CATH Search:   
       by CATH code, keyword
QuickSearch:   
by PDB,NDB,UniProt,PROSITE Code or Search Term(s)  
(use 'Shift Left-Click' to collapse/expand all levels downwards; use 'Control Left-Click' to collapse/expand all levels upwards)
 
(-)
Class: Mainly Beta (13760)
(-)
Architecture: Beta Barrel (4804)
(-)
Topology: Cathepsin D, subunit A; domain 1 (745)
(-)
Homologous Superfamily: Acid Proteases (745)
(-)
[unclassified] (17)
1CPIA:1-99; B:1-99REGIOSELECTIVE STRUCTURAL AND FUNCTIONAL MIMICRY OF PEPTIDES. DESIGN OF HYDROLYTICALLY STABLE CYCLIC PEPTIDOMIMETIC INHIBITORS OF HIV-1 PROTEASE
1D4KA:1-99; B:1-99HIV-1 PROTEASE COMPLEXED WITH A MACROCYCLIC PEPTIDOMIMETIC INHIBITOR
1D4LA:1-99; B:1-99HIV-1 PROTEASE COMPLEXED WITH A MACROCYCLIC PEPTIDOMIMETIC INHIBITOR
1TSQA:1-99; B:1-99CRYSTAL STRUCTURE OF AP2V SUBSTRATE VARIANT OF NC-P1 DECAMER PEPTIDE IN COMPLEX WITH V82A/D25N HIV-1 PROTEASE MUTANT
1TSUA:1-99; B:1-99CRYSTAL STRUCTURE OF DECAMER NCP1 SUBSTRATE PEPTIDE IN COMPLEX WITH WILD-TYPE D25N HIV-1 PROTEASE VARIANT
1Z1HA:1-99; B:101-199HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 3
1Z1RA:1-99; B:101-199HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 2
2J9KA:1-99; B:1-99ATOMIC-RESOLUTION CRYSTAL STRUCTURE OF CHEMICALLY-SYNTHESIZED HIV-1 PROTEASE COMPLEXED WITH INHIBITOR MVT-101
2O40A:1-102; A:103-203CRYSTAL STRUCTURE OF A CHEMICALLY SYNTHESIZED 203 AMINO ACID 'COVALENT DIMER' HIV-1 PROTEASE MOLECULE
3BXRA:1-99; B:101-199CRYSTAL STRUCTURES OF HIGHLY CONSTRAINED SUBSTRATE AND HYDROLYSIS PRODUCTS BOUND TO HIV-1 PROTEASE. IMPLICATIONS FOR CATALYTIC MECHANISM
3BXSA:1-99; B:101-199CRYSTAL STRUCTURES OF HIGHLY CONSTRAINED SUBSTRATE AND HYDROLYSIS PRODUCTS BOUND TO HIV-1 PROTEASE. IMPLICATIONS FOR CATALYTIC MECHANISM
3DCKA:1-99; B:1-99X-RAY STRUCTURE OF D25N CHEMICAL ANALOGUE OF HIV-1 PROTEASE COMPLEXED WITH KETOMETHYLENE ISOSTERE INHIBITOR
3DCRA:1-99; B:1-99X-RAY STRUCTURE OF HIV-1 PROTEASE AND HYDRATED FORM OF KETOMETHYLENE ISOSTERE INHIBITOR
3FSMA:1-102; A:103-203CRYSTAL STRUCTURE OF A CHEMICALLY SYNTHESIZED 203 AMINO ACID 'COVALENT DIMER' [L-ALA51,D-ALA51'] HIV-1 PROTEASE MOLECULE
3HBOA:1-99; B:1-99CRYSTAL STRUCTURE OF CHEMICALLY SYNTHESIZED [D-ALA51/51']HIV-1 PROTEASE
3HDKA:1-99; B:1-99CRYSTAL STRUCTURE OF CHEMICALLY SYNTHESIZED [AIB51/51']HIV-1 PROTEASE
(-)
2_ (1)
1ER8E:171-326; E:2-170THE ACTIVE SITE OF ASPARTIC PROTEINASES
(-)
Aspergillus oryzae. Organism_taxid: 5062 (2)
1IZDA:171-322; A:6-170CRYSTAL STRUCTURE OF ASPERGILLUS ORYZAE ASPARTIC PROTEINASE
1IZEA:171-322; A:6-170CRYSTAL STRUCTURE OF ASPERGILLUS ORYZAE ASPARTIC PROTEINASE COMPLEXED WITH PEPSTATIN
(-)
Aspergillus phoenicis. Organism_taxid: 5063 (1)
1IBQA:170-324; B:170-324; A:5-169; B:5-169ASPERGILLOPEPSIN FROM ASPERGILLUS PHOENICIS
(-)
Atlantic cod (Gadus morhua) (1)
1AM5A:171-324; A:1-170THE CRYSTAL STRUCTURE AND PROPOSED AMINO ACID SEQUENCE OF A PEPSIN FROM ATLANTIC COD (GADUS MORHUA)
(-)
Avian myeloblastosis-associated virus. Organism_taxid: 11960 (1)
1MVPA:1-124; B:1-124STRUCTURAL STUDIES OF THE RETROVIRAL PROTEINASE FROM AVIAN MYELOBLASTOSIS ASSOCIATED VIRUS
(-)
Baker's yeast (Saccharomyces cerevisiae) (11)
1DP5A:171-325; A:0-170THE STRUCTURE OF PROTEINASE A COMPLEXED WITH A IA3 MUTANT INHIBITOR
1DPJA:171-325; A:0-170THE STRUCTURE OF PROTEINASE A COMPLEXED WITH IA3 PEPTIDE INHIBITOR
1FMUA:174-326; A:0-173STRUCTURE OF NATIVE PROTEINASE A IN P3221 SPACE GROUP.
1FMXA:175-328; A:1-174; B:1-174; B:175-328STRUCTURE OF NATIVE PROTEINASE A IN THE SPACE GROUP P21
1FQ4A:171-325; A:0-170CRYSTAL STRUCTURE OF A COMPLEX BETWEEN HYDROXYETHYLENE INHIBITOR CP-108,420 AND YEAST ASPARTIC PROTEINASE A
1FQ5A:171-325; A:0-170X-RAY STRUCTURE OF A CYCLIC STATINE INHIBITOR PD-129,541 BOUND TO YEAST PROTEINASE A
1FQ6A:171-325; A:0-170X-RAY STRUCTURE OF GLYCOL INHIBITOR PD-133,450 BOUND TO SACCHAROPEPSIN
1FQ7A:171-325; A:0-170X-RAY STRUCTURE OF INHIBITOR CP-72,647 BOUND TO SACCHAROPEPSIN
1FQ8A:171-325; A:0-170X-RAY STRUCTURE OF DIFLUOROSTATINE INHIBITOR CP81,198 BOUND TO SACCHAROPEPSIN
1G0VA:171-325; A:0-170THE STRUCTURE OF PROTEINASE A COMPLEXED WITH A IA3 MUTANT, MVV
2JXRA:171-325; A:0-170STRUCTURE OF YEAST PROTEINASE A
(-)
Bread mold (Rhizopus chinensis) (3)
4APRE:6-174; E:175-323STRUCTURES OF COMPLEXES OF RHIZOPUSPEPSIN WITH PEPSTATIN AND OTHER STATINE-CONTAINING INHIBITORS
5APRE:6-174; E:175-323STRUCTURES OF COMPLEXES OF RHIZOPUSPEPSIN WITH PEPSTATIN AND OTHER STATINE-CONTAINING INHIBITORS
6APRE:6-174; E:175-323STRUCTURES OF COMPLEXES OF RHIZOPUSPEPSIN WITH PEPSTATIN AND OTHER STATINE-CONTAINING INHIBITORS
(-)
Bread wheat (Triticum aestivum) (3)
1T6EX:1-180; X:181-381CRYSTAL STRUCTURE OF THE TRITICUM AESTIVUM XYLANASE INHIBITOR I
1T6GA:1-180; B:1-180; A:181-381; B:181-381CRYSTAL STRUCTURE OF THE TRITICUM AESTIVUM XYLANASE INHIBITOR-I IN COMPLEX WITH ASPERGILLUS NIGER XYLANASE-I
2B42A:1-180; A:181-381CRYSTAL STRUCTURE OF THE TRITICUM XYLANSE INHIBITOR-I IN COMPLEX WITH BACILLUS SUBTILIS XYLANASE
(-)
Candida albicans. Organism_taxid: 5476. (3)
1EAGA:173-342; A:1-172SECRETED ASPARTIC PROTEINASE (SAP2) FROM CANDIDA ALBICANS COMPLEXED WITH A70450
2H6SA:173-342; A:1-172SECRETED ASPARTIC PROTEINASE (SAP) 3 FROM CANDIDA ALBICANS
2H6TA:173-342; A:1-172SECRETED ASPARTIC PROTEINASE (SAP) 3 FROM CANDIDA ALBICANS COMPLEXED WITH PEPSTATIN A
(-)
Candida albicans. Organism_taxid: 5476. Strain: val-1. Variant: pathogenic clinical isolate from skin. (1)
1ZAPA:173-341; A:1-172SECRETED ASPARTIC PROTEASE FROM C. ALBICANS
(-)
Candida parapsilosis. Organism_taxid: 5480. Strain: p-69. (1)
3FV3A:176-339; B:176-339; B:1-175; C:1-175; E:1-175; F:1-175; G:1-175; H:1-175; C:176-339; D:176-339; E:176-339; F:176-339; G:176-339; H:176-339; D:1-175; A:1-175SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
(-)
Candida tropicalis. Organism_taxid: 5482. (1)
1J71A:174-334; A:1-173STRUCTURE OF THE EXTRACELLULAR ASPARTIC PROTEINASE FROM CANDIDA TROPICALIS YEAST.
(-)
Cattle (Bos taurus) (4)
1CMSA:172-323; A:3-171THE THREE-DIMENSIONAL STRUCTURE OF RECOMBINANT BOVINE CHYMOSIN AT 2.3 ANGSTROMS RESOLUTION
1CZIE:171-325; E:-1-170CHYMOSIN COMPLEX WITH THE INHIBITOR CP-113972
3CMSA:171-325; A:1-170ENGINEERING ENZYME SUB-SITE SPECIFICITY: PREPARATION, KINETIC CHARACTERIZATION AND X-RAY ANALYSIS AT 2.0-ANGSTROMS RESOLUTION OF VAL111PHE SITE-MUTATED CALF CHYMOSIN
4CMSA:171-325; A:1-170X-RAY ANALYSES OF ASPARTIC PROTEINASES IV. STRUCTURE AND REFINEMENT AT 2.2 ANGSTROMS RESOLUTION OF BOVINE CHYMOSIN
(-)
Chesnut blight fungus (Cryphonectria parasitica) (3)
1OD1A:175-330; A:5-174ENDOTHIAPEPSIN PD135,040 COMPLEX
2JJIA:175-329; A:5-174ENDOTHIAPEPSIN IN COMPLEX WITH A GEM-DIOL INHIBITOR.
2JJJA:175-329; A:5-174ENDOTHIAPEPSIN IN COMPLEX WITH A GEM-DIOL INHIBITOR.
(-)
Chestnut blight fungus (Cryphonectria parasitica) (20)
1EEDP:171-326; P:2-170X-RAY CRYSTALLOGRAPHIC ANALYSIS OF INHIBITION OF ENDOTHIAPEPSIN BY CYCLOHEXYL RENIN INHIBITORS
1ENTE:171-326; E:2-170X-RAY ANALYSES OF ASPARTIC PROTEINASES. THE THREE-DIMENSIONAL STRUCTURE AT 2.1 ANGSTROMS RESOLUTION OF ENDOTHIAPEPSIN
1EPNE:171-326; E:2-170A STRUCTURAL COMPARISON OF 21 INHIBITOR COMPLEXES OF THE ASPARTIC PROTEINASE FROM ENDOTHIA PARASITICA
1EPOE:171-326; E:2-170ENDOTHIA ASPARTIC PROTEINASE (ENDOTHIAPEPSIN) COMPLEXED WITH CP-81,282 (MOR PHE NLE CHF NME)
1EPPE:171-326; E:2-170ENDOTHIA ASPARTIC PROTEINASE (ENDOTHIAPEPSIN) COMPLEXED WITH PD-130, 693 (MAS PHE LYS+MTF STA MBA)
1EPQE:171-326; E:2-170ENDOTHIA ASPARTIC PROTEINASE (ENDOTHIAPEPSIN) COMPLEXED WITH PD-133, 450 (SOT PHE GLY+SCC GCL)
1EPRE:171-326; E:2-170ENDOTHIA ASPARTIC PROTEINASE (ENDOTHIAPEPSIN) COMPLEXED WITH PD-135, 040
1GKTA:175-329; A:5-174NEUTRON LAUE DIFFRACTION STRUCTURE OF ENDOTHIAPEPSIN COMPLEXED WITH TRANSITION STATE ANALOGUE INHIBITOR H261
1OEWA:174-328; A:5-173ATOMIC RESOLUTION STRUCTURE OF NATIVE ENDOTHIAPEPSIN
1OEXA:174-328; A:5-173ATOMIC RESOLUTION STRUCTURE OF ENDOTHIAPEPSIN IN COMPLEX WITH A HYDROXYETHYLENE TRANSITION STATE ANALOGUE INHIBITOR H261
2ER0E:171-326; E:2-170X-RAY STUDIES OF ASPARTIC PROTEINASE-STATINE INHIBITOR COMPLEXES
2ER7E:171-326; E:2-170X-RAY ANALYSES OF ASPARTIC PROTEINASES.III. THREE-DIMENSIONAL STRUCTURE OF ENDOTHIAPEPSIN COMPLEXED WITH A TRANSITION-STATE ISOSTERE INHIBITOR OF RENIN AT 1.6 ANGSTROMS RESOLUTION
2ER9E:171-326; E:2-170X-RAY STUDIES OF ASPARTIC PROTEINASE-STATINE INHIBITOR COMPLEXES.
2V00A:175-330; A:5-174X-RAY CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN COMPLEXED WITH COMPOUND 1
2VS2A:175-329; A:5-174NEUTRON DIFFRACTION STRUCTURE OF ENDOTHIAPEPSIN IN COMPLEX WITH A GEM-DIOL INHIBITOR.
3ER3E:171-326; E:2-170THE ACTIVE SITE OF ASPARTIC PROTEINASES
4ER1E:171-326; E:2-170THE ACTIVE SITE OF ASPARTIC PROTEINASES
4ER2E:171-326; E:2-170THE ACTIVE SITE OF ASPARTIC PROTEINASES
5ER1E:171-326; E:2-170A RATIONAL APPROACH TO THE DESIGN OF ANTIHYPERTENSIVES. X-RAY STUDIES OF COMPLEXES BETWEEN ASPARTIC PROTEINASES AND AMINOALCOHOL RENIN INHIBITORS
5ER2E:171-326; E:2-170HIGH-RESOLUTION X-RAY DIFFRACTION STUDY OF THE COMPLEX BETWEEN ENDOTHIAPEPSIN AND AN OLIGOPEPTIDE INHIBITOR. THE ANALYSIS OF THE INHIBITOR BINDING AND DESCRIPTION OF THE RIGID BODY SHIFT IN THE ENZYME
(-)
Chestnut blight fungus (Endothia parasitica) (5)
1GVTA:175-329; A:5-174ENDOTHIAPEPSIN COMPLEX WITH CP-80,794
1GVUA:175-329; A:5-174ENDOTHIAPEPSIN COMPLEX WITH H189
1GVVA:175-329; A:5-174FIVE ATOMIC RESOLUTION STRUCTURES OF ENDOTHIAPEPSIN INHIBITOR COMPLEXES; IMPLICATIONS FOR THE ASPARTIC PROTEINASE MECHANISM
1GVWA:175-329; A:5-174ENDOTHIAPEPSIN COMPLEX WITH PD-130,328
1GVXA:175-329; A:5-174ENDOTHIAPEPSIN COMPLEXED WITH H256
(-)
Chinensis (Rhizopus microsporus var) (5)
1UH7A:6-174; A:175-323CRYSTAL STRUCTURE OF RHIZOPUSPEPSIN AT PH 4.6
1UH8A:6-174; A:175-323CRYSTAL STRUCTURE OF RHIZOPUSPEPSIN AT PH 8.0
1UH9A:6-174; A:175-323CRYSTAL STRUCTURE OF RHIZOPUSPEPSIN AT PH 7.0
2APRA:6-174; A:175-323STRUCTURE AND REFINEMENT AT 1.8 ANGSTROMS RESOLUTION OF THE ASPARTIC PROTEINASE FROM RHIZOPUS CHINENSIS
3APRE:6-174; E:175-323BINDING OF A REDUCED PEPTIDE INHIBITOR TO THE ASPARTIC PROTEINASE FROM RHIZOPUS CHINENSIS. IMPLICATIONS FOR A MECHANISM OF ACTION
(-)
Cryphonectria parasitica. Organism_taxid: 5116 (1)
4APEA:171-326; A:2-170THE ACTIVE SITE OF ASPARTIC PROTEINASES
(-)
Cryphonectria parasitica. Organism_taxid: 5116. (5)
1EPLE:171-326; E:2-170A STRUCTURAL COMPARISON OF 21 INHIBITOR COMPLEXES OF THE ASPARTIC PROTEINASE FROM ENDOTHIA PARASITICA
1EPME:171-326; E:2-170A STRUCTURAL COMPARISON OF 21 INHIBITOR COMPLEXES OF THE ASPARTIC PROTEINASE FROM ENDOTHIA PARASITICA
2ER6E:171-326; E:2-170THE STRUCTURE OF A SYNTHETIC PEPSIN INHIBITOR COMPLEXED WITH ENDOTHIAPEPSIN.
3ER5E:171-326; E:2-170THE ACTIVE SITE OF ASPARTIC PROTEINASES
4ER4E:171-326; E:2-170HIGH-RESOLUTION X-RAY ANALYSES OF RENIN INHIBITOR-ASPARTIC PROTEINASE COMPLEXES
(-)
Cynara cardunculus. Organism_taxid: 4265. (1)
1B5FB:243-326; D:243-326; C:1-238; A:0-238NATIVE CARDOSIN A FROM CYNARA CARDUNCULUS L.
(-)
Endothia parasitica. Organism_taxid: 5116 (2)
1E81E:171-326; E:2-170ENDOTHIAPEPSIN COMPLEX WITH RENIN INHIBITOR MERCK-KGAA-EMD61395
1E82E:171-326; E:2-170ENDOTHIAPEPSIN COMPLEX WITH RENIN INHIBITOR MERCK-KGAA-EMD59601
(-)
Endothia parasitica. Organism_taxid: 5116. (2)
1E5OE:171-326; E:2-170ENDOTHIAPEPSIN COMPLEX WITH INHIBITOR DB2
1E80E:171-326; E:2-170ENDOTHIAPEPSIN COMPLEX WITH RENIN INHIBITOR MERCK-KGAA-EMD56133
(-)
Equine infectious anemia virus. Organism_taxid: 11665. (2)
1FMBA:1-104EIAV PROTEASE COMPLEXED WITH THE INHIBITOR HBY-793
2FMBA:1-104EIAV PROTEASE COMPLEXED WITH AN INHIBITOR LP-130
(-)
Feline immunodeficiency virus (isolate petaluma). Organism_taxid: 11674. Strain: (isolate petaluma). (2)
5FIVA:5-116STRUCTURAL STUDIES OF HIV AND FIV PROTEASES COMPLEXED WITH AN EFFICIENT INHIBITOR OF FIV PR
6FIVA:5-116STRUCTURAL STUDIES OF HIV AND FIV PROTEASES COMPLEXED WITH AN EFFICIENT INHIBITOR OF FIV PR
(-)
Feline immunodeficiency virus (isolate petaluma). Organism_taxid: 11674. Strain: isolate petaluma. (1)
2HAHA:5-116THE STRUCTURE OF FIV 12S PROTEASE IN COMPLEX WITH TL-3
(-)
Feline immunodeficiency virus. Organism_taxid: 11673 (1)
1B11A:4-116STRUCTURE OF FELINE IMMUNODEFICIENCY VIRUS PROTEASE COMPLEXED WITH TL-3-093
(-)
Feline immunodeficiency virus. Organism_taxid: 11673. (2)
1FIVA:4-116STRUCTURE OF AN INHIBITOR COMPLEX OF PROTEINASE FROM FELINE IMMUNODEFICIENCY VIRUS
4FIVA:4-116FIV PROTEASE COMPLEXED WITH AN INHIBITOR LP-130
(-)
Feline immunodeficiency virus. Organism_taxid: 11673. Cell_line: bl21. (2)
2FIVA:4-116; B:4-116CRYSTAL STRUCTURE OF FELINE IMMUNODEFICIENCY VIRUS PROTEASE COMPLEXED WITH A SUBSTRATE
3FIVA:6-116; B:6-116CRYSTAL STRUCTURE OF FELINE IMMUNODEFICIENCY VIRUS PROTEASE COMPLEXED WITH A SUBSTRATE
(-)
Hiv-1 (Human immunodeficiency virus 1) (5)
2QAKA:1-99; B:1-99HIV-1 PR MUTANT IN COMPLEX WITH NELFINAVIR
2QHCA:1-99; B:1-99THE INFLUENCE OF I47A MUTATION ON REDUCED SUSCEPTIBILITY TO THE PROTEASE INHIBITOR LOPINAVIR
2RKFA:1-99; B:1-99HIV-1 PR RESISTANT MUTANT + LPV
2RKGA:1-100; B:1-100HIV-1 PR RESISTANT MUTANT + LPV
3I7EA:1-99; B:1-99CO-CRYSTAL STRUCTURE OF HIV-1 PROTEASE BOUND TO A MUTANT RESISTANT INHIBITOR UIC-98038
(-)
Hiv-1 (Human immunodeficiency virus type 1 (z2/cdc-z34 isolate)) (1)
2WL0A:1-99; B:101-199HIV-1 PROTEASE INHIBITORS CONTAINING A TERTIARY ALCOHOL IN THE TRANSITION-STATE MIMIC WITH IMPROVED CELL-BASED ANTIVIRAL ACTIVITY
(-)
Hiv-1 (Human immunodeficiency virus type 1 ( isolate z2/cdc-z34 group m subtype d)) (1)
2WKZA:1-99; B:101-199HIV-1 PROTEASE INHIBITORS CONTAINING A TERTIARY ALCOHOL IN THE TRANSITION-STATE MIMIC WITH IMPROVED CELL-BASED ANTIVIRAL ACTIVITY
(-)
Hiv-1 (Human immunodeficiency virus type 1 (bru isolate)) (6)
3GGT  [entry was replaced by entry 3U7S without any CATH domain information]
3H5BA:1-99; B:101-199CRYSTAL STRUCTURE OF WILD TYPE HIV-1 PROTEASE WITH NOVEL P1'-LIGAND GRL-02031
3I6OA:1-99; B:101-199CRYSTAL STRUCTURE OF WILD TYPE HIV-1 PROTEASE WITH MACROCYCLIC INHIBITOR GRL-0216A
3JVWA:1-99; B:101-199HIV-1 PROTEASE MUTANT G86A WITH SYMMETRIC INHIBITOR DMP323
3JVYA:1-99; B:101-199HIV-1 PROTEASE MUTANT G86A WITH DARUNAVIR
3JW2A:1-99; B:101-199HIV-1 PROTEASE MUTANT G86S WITH DARUNAVIR
(-)
Hiv-1 (Human immunodeficiency virus type 1) (14)
2Z54A:1-99; B:1-99THE INFLUENCE OF I47A MUTATION ON REDUCED SUSCEPTIBILITY TO THE PROTEASE INHIBITOR LOPINAVIR
2ZGAA:1-99HIV-1 PROTEASE IN COMPLEX WITH A DIMETHYLALLYL DECORATED PYRROLIDINE BASED INHIBITOR (HEXAGONAL SPACE GROUP)
3CKTA:1-99; B:1-99HIV-1 PROTEASE IN COMPLEX WITH A DIMETHYLALLYL DECORATED PYRROLIDINE BASED INHIBITOR (ORTHOROMBIC SPACE GROUP)
3D1YA:1-99; B:101-199CRYSTAL STRUCTURE OF HIV-1 MUTANT I54V AND INHIBITOR SAQUINA
3D1ZA:1-99; B:1-99CRYSTAL STRUCTURE OF HIV-1 MUTANT I54M AND INHIBITOR DARUNAVIR
3D20A:1-99; B:101-199CRYSTAL STRUCTURE OF HIV-1 MUTANT I54V AND INHIBITOR DARUNAVIA
3DJKA:1-99; B:101-199WILD TYPE HIV-1 PROTEASE WITH POTENT ANTIVIRAL INHIBITOR GRL-0255A
3DK1A:1-99; B:101-199WILD TYPE HIV-1 PROTEASE WITH POTENT ANTIVIRAL INHIBITOR GRL-0105A
3K4VA:1-99; B:1-99; C:1-99; D:1-99NEW CRYSTAL FORM OF HIV-1 PROTEASE/SAQUINAVIR STRUCTURE REVEALS CARBAMYLATION OF N-TERMINAL PROLINE
3KDBA:1-99; B:1-99CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K, L33I, L63I) IN COMPLEX WITH KNI-10006
3KDCA:1-99; B:1-99CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K, L33I, L63I) IN COMPLEX WITH KNI-10074
3KDDA:1-99; B:1-99CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K, L33I, L63I) IN COMPLEX WITH KNI-10265
3KT2A:1-99; A:1001-1099CRYSTAL STRUCTURE OF N88D MUTANT HIV-1 PROTEASE
3KT5A:1-99; A:1001-1099CRYSTAL STRUCTURE OF N88S MUTANT HIV-1 PROTEASE
(-)
Hiv-1 (Human immunodeficiency virus) (4)
1W5VA:1-99; B:1-99HIV-1 PROTEASE IN COMPLEX WITH FLUORO SUBSTITUTED DIOL-BASED C2-SYMMETRIC INHIBITOR
1W5WA:1-99; B:1-99HIV-1 PROTEASE IN COMPLEX WITH FLUORO SUBSTITUTED DIOL-BASED C2-SYMMETRIC INHIBITOR
1W5XA:1-99; B:1-99HIV-1 PROTEASE IN COMPLEX WITH FLUORO SUBSTITUTED DIOL-BASED C2-SYMMETRIC INHIBITOR
1W5YA:1-99; B:1-99HIV-1 PROTEASE IN COMPLEX WITH FLUORO SUBSTITUTED DIOL-BASED C2-SYMMETRIC INHIBITOR
(-)
Hiv-1 m:b_arv2/sf2. Hiv-1. Organism_taxid: 11685. (4)
3EKPA:1-99; C:1-99; D:1-99; B:1-99CRYSTAL STRUCTURE OF THE INHIBITOR AMPRENAVIR (APV) IN COMPLEX WITH A MULTI-DRUG RESISTANT HIV-1 PROTEASE VARIANT (L10I/G48V/I54V/V64I/V82A)REFER: FLAP+ IN CITATION
3EKTA:1-99; B:1-99; C:1-99; D:1-99CRYSTAL STRUCTURE OF THE INHIBITOR DARUNAVIR (DRV) IN COMPLEX WITH A MULTI-DRUG RESISTANT HIV-1 PROTEASE VARIANT (L10F/G48V/I54V/V64I/V82A) (REFER: FLAP+ IN CITATION.)
3EKWA:1-99; B:1-99CRYSTAL STRUCTURE OF THE INHIBITOR ATAZANAVIR (ATV) IN COMPLEX WITH A MULTI-DRUG RESISTANCE HIV-1 PROTEASE VARIANT (L10I/G48V/I54V/V64I/V82A) REFER: FLAP+ IN CITATION.
3EL0A:1-99; B:1-99CRYSTAL STRUCTURE OF THE INHIBITOR NELFINAVIR (NFV) IN COMPLEX WITH A MULTI-DRUG RESISTANT HIV-1 PROTEASE VARIANT (L10I/G48V/I54V/V64I/V82A) (REFER: FLAP+ IN CITATION)
(-)
Hiv-1 m:b_arv2/sf2. Hiv-1. Organism_taxid: 11685. Strain: hxb2. (11)
3EKQA:1-99; B:1-99CRYSTAL STRUCTURE OF INHIBITOR SAQUINAVIR (SQV) IN COMPLEX WITH MULTI-DRUG RESISTANT HIV-1 PROTEASE (L63P/V82T/I84V) (REFERRED TO AS ACT IN PAPER)
3EKVA:1-99; B:1-99CRYSTAL STRUCTURE OF THE WILD TYPE HIV-1 PROTEASE WITH THE INHIBITOR, AMPRENAVIR
3EKXA:1-99; B:1-99CRYSTAL STRUCTURE OF THE WILD-TYPE HIV-1 PROTEASE WITH THE INHIBITOR, NELFINAVIR
3EKYA:1-99; B:1-99CRYSTAL STRUCTURE OF WILD-TYPE HIV PROTEASE IN COMPLEX WITH THE INHIBITOR, ATAZANAVIR
3EL1A:1-99; B:1-99CRYSTAL STRUCTURE OF WILD-TYPE HIV PROTEASE IN COMPLEX WITH THE INHIBITOR, ATAZANAVIR
3EL4A:1-99; B:1-99CRYSTAL STRUCTURE OF INHIBITOR SAQUINAVIR (SQV) COMPLEXED WITH THE MULTIDRUG HIV-1 PROTEASE VARIANT L63P/V82T/I84V
3EL5A:1-99; B:1-99CRYSTAL STRUCTURE OF NELFINAVIR (NFV) COMPLEXED WITH A MULTIDRUG VARIANT (ACT) (V82T/I84V) OF HIV-1 PROTEASE
3EL9A:1-99; B:1-99CRYSTAL STRUCTURE OF ATAZANAVIR (ATV) IN COMPLEX WITH A MULTIDRUG HIV-1 PROTEASE (V82T/I84V)
3EM3A:1-99; B:1-99CRYSTAL STRUCTURE OF AMPRENAVIR (APV) IN COMPLEX WITH A DRUG RESISTANT HIV-1 PROTEASE VARIANT (I50L/A71V).
3EM4A:1-99; B:1-99; U:1-99; V:1-99CRYSTAL STRUCTURE OF ATAZANAVIR (ATV) IN COMPLEX WITH I50L/A71V DRUG-RESISTANT HIV-1 PROTEASE
3EM6A:1-99; B:1-99CRYSTAL STRUCTURE OF I50L/A71V MUTANT OF HIV-1 PROTEASE IN COMPLEX WITH INHIBITOR DARUNAVIR
(-)
Hiv-1 m:b_arv2/sf2. Organism_taxid: 11685. Strain: sf2. (3)
2NXDA:1-99; B:1-99STRUCTURE OF HIV-1 PROTEASE D25N COMPLEXED WITH RT-RH ANALOGUE PEPTIDE GLY-ALA-ASP-ILE-PHE*TYR-LEU-ASP-GLY-ALA
2NXLA:1-99; B:1-99STRUCTURE OF HIV-1 PROTEASE D25N COMPLEXED WITH THE RT-RH ANALOGUE PEPTIDE GLY-ALA-GLU-VAL-PHE*TYR-VAL-ASP-GLY-ALA
2NXMA:1-99; B:1-99STRUCTURE OF HIV-1 PROTEASE D25N COMPLEXED WITH THE RT-RH ANALOGUE PEPTIDE GLY-ALA-GLN-THR-PHE*TYR-VAL-ASP-GLY-ALA
(-)
Hiv-1 m:b_hxb2r. Organism_taxid: 11706. (1)
1ODYA:1-99; B:1-99HIV-1 PROTEASE COMPLEXED WITH AN INHIBITOR LP-130
(-)
Hiv-1 m:b_hxb2r. Organism_taxid: 11706. Cell_line: s2. (1)
3PHVA:1-99X-RAY ANALYSIS OF HIV-1 PROTEINASE AT 2.7 ANGSTROMS RESOLUTION CONFIRMS STRUCTURAL HOMOLOGY AMONG RETROVIRAL ENZYMES
(-)
Homo sapiens. Organism_taxid: 9606. (4)
2VA6A:14-146; A:147-386X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 24
3DUYA:14-146; B:14-146; A:147-385; B:147-385; C:147-385; C:14-146CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-AFJ144
3DV1A:14-146; A:147-385; B:147-386; C:147-385; B:14-146; C:14-146CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-ARV999
3DV5A:14-146; A:147-385; B:147-385; C:147-385; B:14-146; C:14-146CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-BAV544
(-)
House mouse (Mus musculus) (1)
1SMRA:171-325; C:171-325; E:171-325; G:171-325; A:1-170; C:1-170; E:1-170; G:1-170THE 3-D STRUCTURE OF MOUSE SUBMAXILLARY RENIN COMPLEXED WITH A DECAPEPTIDE INHIBITOR CH-66 BASED ON THE 4-16 FRAGMENT OF RAT ANGIOTENSINOGEN
(-)
Human (Homo sapiens) (161)
1AVFA:172-327; J:172-328; A:2-171; J:2-171ACTIVATION INTERMEDIATE 2 OF HUMAN GASTRICSIN FROM HUMAN STOMACH
1BBSA:171-325; A:1-170X-RAY ANALYSES OF PEPTIDE INHIBITOR COMPLEXES DEFINE THE STRUCTURAL BASIS OF SPECIFICITY FOR HUMAN AND MOUSE RENINS
1BILA:171-325; B:171-325; B:1-170; A:1-170CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS
1BIMA:171-325; B:171-325; B:1-170; A:1-170CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS
1FKNA:14-146; B:14-146; A:147-385; B:147-385STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR
1FLHA:171-325; A:1-170CRYSTAL STRUCTURE OF HUMAN UROPEPSIN AT 2.45 A RESOLUTION
1HRNA:171-325; B:171-325; B:1-170; A:1-170HIGH RESOLUTION CRYSTAL STRUCTURES OF RECOMBINANT HUMAN RENIN IN COMPLEX WITH POLYHYDROXYMONOAMIDE INHIBITORS
1HTRB:172-328; B:1-171CRYSTAL AND MOLECULAR STRUCTURES OF HUMAN PROGASTRICSIN AT 1.62 ANGSTROMS RESOLUTION
1LYAA:1-97; C:1-97; B:106-346; D:106-346CRYSTAL STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN D: IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN
1LYBA:1-97; C:1-97; B:106-346; D:106-346CRYSTAL STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN D: IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN
1LYWA:3-97; C:3-97; E:3-97; G:3-97; B:106-346; D:106-346; F:106-346; H:106-346CATHEPSIN D AT PH 7.5
1M4HA:14-146; A:147-385; B:147-385; B:14-146CRYSTAL STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR OM00-3
1PSNA:171-325; A:1-170THE CRYSTAL STRUCTURE OF HUMAN PEPSIN AND ITS COMPLEX WITH PEPSTATIN
1PSOE:171-325; E:1-170THE CRYSTAL STRUCTURE OF HUMAN PEPSIN AND ITS COMPLEX WITH PEPSTATIN
1Q9PA:1-95SOLUTION STRUCTURE OF THE MATURE HIV-1 PROTEASE MONOMER
1QRPE:171-325; E:1-170HUMAN PEPSIN 3A IN COMPLEX WITH A PHOSPHONATE INHIBITOR IVA-VAL-VAL-LEU(P)-(O)PHE-ALA-ALA-OME
1RNEA:171-325; A:1-170THE CRYSTAL STRUCTURE OF RECOMBINANT GLYCOSYLATED HUMAN RENIN ALONE AND IN COMPLEX WITH A TRANSITION STATE ANALOG INHIBITOR
1SGZA:14-146; A:147-385; B:147-385; C:147-385; D:147-385; B:14-146; C:14-146; D:14-146CRYSTAL STRUCTURE OF UNBOUND BETA-SECRETASE CATALYTIC DOMAIN.
1TQFA:14-146; A:147-385CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
1W50A:14-146; A:147-385APO STRUCTURE OF BACE (BETA SECRETASE)
1W51A:14-146; A:147-385BACE (BETA SECRETASE) IN COMPLEX WITH A NANOMOLAR NON-PEPTIDIC INHIBITOR
1XN2A:14-146; B:14-146; A:147-385; B:147-385; C:147-385; D:147-385; C:14-146; D:14-146NEW SUBSTRATE BINDING POCKETS FOR BETA-SECRETASE.
1XN3A:14-146; A:147-385; B:147-385; C:147-385; D:147-385; B:14-146; C:14-146; D:14-146CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A LONG INHIBITOR WITH ADDITIONAL UPSTREAM RESIDUES.
1XS7D:14-146; D:147-385CRYSTAL STRUCTURE OF A CYCLOAMIDE-URETHANE-DERIVED NOVEL INHIBITOR BOUND TO HUMAN BRAIN MEMAPSIN 2 (BETA-SECRETASE).
1YM2A:14-146; A:147-385; C:147-385; B:147-385; B:14-146; C:14-146CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AUR200
1YM4A:14-146; B:14-146; C:14-146; B:147-385; A:147-385; C:147-385CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AMK640
2B8LA:14-146; A:147-385CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
2B8VA:14-146; A:147-385CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE COMPLEXED WITH L-L000430,469
2EWYA:30-162; B:30-162; C:30-162; D:30-162; A:163-398; B:163-398; C:163-398; D:163-398CRYSTAL STRUCTURE OF HUMAN BACE2 IN COMPLEX WITH A HYDROXYETHYLENAMINE TRANSITION-STATE INHIBITOR
2F3EA:14-146; A:147-385; B:147-385; C:147-385; B:14-146; C:14-146CRYSTAL STRUCTURE OF THE BACE COMPLEX WITH AXQ093, A MACROCYCLIC INHIBITOR
2F3FA:14-146; B:14-146; C:14-146; A:147-385; B:147-385; C:147-385CRYSTAL STRUCTURE OF THE BACE COMPLEX WITH BDF488, A MACROCYCLIC INHIBITOR
2FDPA:14-146; B:14-146; C:14-146; B:147-385; A:147-385; C:147-385CRYSTAL STRUCTURE OF BETA-SECRETASE COMPLEXED WITH AN AMINO-ETHYLENE INHIBITOR
2FS4A:175-332; B:175-332; A:3-174; B:3-174KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
2G1NA:177-334; B:177-334; A:3-176; B:3-176KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING
2G1OA:177-334; B:177-334; A:3-176; B:3-176KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING
2G1RA:177-334; B:177-334; A:3-176; B:3-176KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
2G1SA:177-334; B:177-334; A:3-176; B:3-176KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
2G1YA:177-334; B:177-334; A:3-176; B:3-176KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING
2G20A:177-334; B:177-334; A:3-176; B:3-176KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
2G21A:175-332; B:175-332; A:3-174; B:3-174KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING
2G22A:177-334; B:177-334; A:3-176; B:3-176KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING
2G24A:175-332; B:175-332; A:3-174; B:3-174KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING
2G26A:175-332; B:175-332; A:3-174; B:3-174KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING
2G27A:175-332; B:175-332; A:3-174; B:3-174KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING
2G94A:14-146; B:14-146; C:14-146; D:14-146; A:147-385; B:147-385; C:147-385; D:147-385CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A POTENT AND HIGHLY SELECTIVE INHIBITOR.
2HIZA:14-146; B:14-146; C:14-146; A:147-385; B:147-386; C:147-386CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE (BACE) IN THE PRESENCE OF AN INHIBITOR
2HM1A:14-146; A:147-386CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE (BACE) IN THE PRESENCE OF AN INHIBITOR (2)
2I4QA:177-335; B:177-335; A:0-176; B:0-176HUMAN RENIN/PF02342674 COMPLEX
2IQGA:14-146; A:147-386CRYSTAL STRUCTURE OF HYDROXYETHYL SECONDARY AMINE-BASED PEPTIDOMIMETIC INHIBITOR OF HUMAN BETA-SECRETASE (BACE)
2IRZA:14-146; A:147-385CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE COMPLEXED WITH INHIBITOR
2IS0A:14-146; A:147-385CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE COMPLEXED WITH INHIBITOR
2NTRA:14-146; A:147-385CRYSTAL STRUCTURE OF HUMAN BACE-1 BOUND TO INHIBITOR
2OAHA:14-146; A:147-385CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
2OF0A:14-146; A:147-385X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 5
2OHKA:14-146; A:147-385X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH 1-AMINO-ISOQUINOLINE
2OHLA:14-146; A:147-385X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH 2-AMINOQUINOLINE
2OHMA:14-146; A:147-385X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH N~3~-BENZYLPYRIDINE-2,3-DIAMINE
2OHNA:14-146; A:147-385X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH 4-(4-FLUOROBENZYL)PIPERIDINE
2OHPA:14-146; A:147-385X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 3
2OHQA:14-146; A:147-385X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 4
2OHRA:14-146; A:147-385X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 6A
2OHSA:14-146; A:147-385X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 6B
2OHTA:14-146; A:147-385X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 7
2OHUA:14-146; A:147-385X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 8B
2P4JA:14-146; B:14-146; C:14-146; D:14-146; A:147-385; B:147-385; C:147-385; D:147-385CRYSTAL STRUCTURE OF BETA-SECRETASE BOND TO AN INHIBITOR WITH ISOPHTHALAMIDE DERIVATIVES AT P2-P3
2P83A:14-146; B:14-146; C:14-146; A:147-385; B:147-386; C:147-386POTENT AND SELECTIVE ISOPHTHALAMIDE S2 HYDROXYETHYLAMINE INHIBITOR OF BACE1
2P8HA:14-146; A:147-385CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
2PH6A:14-146; A:147-385CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
2PH8A:14-146; A:147-385CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
2Q11A:14-146; B:14-146; C:14-146; A:147-385; B:147-385; C:147-385STRUCTURE OF BACE COMPLEXED TO COMPOUND 1
2Q15A:14-146; A:147-385STRUCTURE OF BACE COMPLEXED TO COMPOUND 3A
2QK5A:75-207; B:208-446; A:208-447; B:75-207STRUCTURE OF BACE1 BOUND TO SCH626485
2QMDA:75-207; B:208-446; A:208-447; B:75-207STRUCTURE OF BACE BOUND TO SCH722924
2QMFA:75-207; B:75-207; B:208-446; A:208-447STRUCTURE OF BACE BOUND TO SCH735310
2QMGA:75-207; B:75-207; B:208-446; A:208-447STRUCTURE OF BACE BOUND TO SCH745966
2QP8A:75-207; B:75-207; B:208-446; A:208-447STRUCTURE OF BACE BOUND TO SCH734723
2QU2A:76-208; A:209-445BACE1 WITH COMPOUND 1
2QU3A:76-208; A:209-445BACE1 WITH COMPOUND 2
2QZKA:14-146; A:147-385CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH I21
2QZLA:14-146; A:147-385CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH IXS
2RENA:182-337; A:7-181STRUCTURE OF RECOMBINANT HUMAN RENIN, A TARGET FOR CARDIOVASCULAR-ACTIVE DRUGS, AT 2.5 ANGSTROMS RESOLUTION
2VA5A:14-146; A:147-386X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 8C
2VA7A:14-146; A:147-386X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 27
2VIEA:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-1-BENZYL-2-HYDROXY-3-((1,1,5-TRIMETHYLHEXYL)AMINO)PROPYL)-3-(ETHYLAMINO)-5-(2-OXOPYRROLIDIN-1-YL)BENZAMIDE
2VIJA:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH 3-(1,1-DIOXIDOTETRAHYDRO-2H-1, 2-THIAZIN-2-YL)-5-(ETHYLAMINO)-N-((1S,2R)-2-HYDROXY-1-( PHENYLMETHYL)-3-(1,2,3,4-TETRAHYDRO-1-NAPHTHALENYLAMINO) PROPYL)BENZAMIDE
2VIYA:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(PENTYLSULFONYL)BENZAMIDE
2VIZA:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(2-OXO-1-PYRROLIDINYL)-5-(PROPYLOXY) BENZAMIDE
2VJ6A:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-(2-OXO-1-PYRROLIDINYL)BENZAMIDE
2VJ7A:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH 3-(ETHYLAMINO)-N-((1S,2R)-2-HYDROXY-1-(PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL) METHYL)AMINO)PROPYL)-5-(2-OXO-1-PYRROLIDINYL)BENZAMIDE
2VJ9A:75-207; A:208-451HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(CYCLOHEXYLAMINO)-2-HYDROXY-1-(PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-(2-OXO-1-PYRROLIDINYL)BENZAMIDE
2VKMA:14-146; A:147-385; B:147-385; C:147-385; D:147-385; B:14-146; C:14-146; D:14-146CRYSTAL STRUCTURE OF GRL-8234 BOUND TO BACE (BETA-SECRETASE)
2VNMA:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH 3-(1,1-DIOXIDOTETRAHYDRO-2H-1, 2-THIAZIN-2-YL)-5-(ETHYLAMINO)-N-((1S,2R)-2-HYDROXY-1-( PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)BENZAMIDE
2VNNA:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH 7-ETHYL-N-((1S,2R)-2-HYDROXY-1-(PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)-1-METHYL-3,4-DIHYDRO-1H-(1,2,5)THIADIAZEPINO(3,4,5-HI)INDOLE-9-CARBOXAMIDE 2,2-DIOXIDE
2WEZA:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH 1-ETHYL-N-((1S,2R)-2-HYDROXY-3-(((3-(METHYLOXY)PHENYL)METHYL)AMINO)-1-(PHENYLMETHYL) PROPYL)-4-(2-OXO-1-PYRROLIDINYL)-1H-INDOLE-6-CARBOXAMIDE
2WF0A:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH 4-ETHYL-N-((1S,2R)-2-HYDROXY-1-(PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)-8-(2-OXO-1-PYRROLIDINYL)-6-QUINOLINECARBOXAMIDE
2WF1A:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH 7-ETHYL-N-((1S,2R)-2-HYDROXY-3-(((3-(METHYLOXY)PHENYL(METHYL)AMINO)-1-(PHENYLMETHYL) PROPYL)-1-METHYL-3,4-DIHYDRO-1H-(1,2,5)THIADIAZEPINO(3,4,5-HI)INDOLE-9-CARBOXAMIDE 2,2-DIOXIDE
2WF2A:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH 8-ETHYL-N-((1S,2R)-2-HYDROXY-3-(((3-(METHYLOXY)PHENYL)METHYL)AMINO)-1-(PHENYLMETHYL) PROPYL)-1-METHYL-3,4,7,8-TETRAHYDRO-1H,6H-(1,2,5) THIADIAZEPINO(5,4,3-DE)QUINOXALINE-10-CARBOXAMIDE 2,2-DIOXIDE
2WF3A:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH 6-(ETHYLAMINO)-N-((1S,2R)-2-HYDROXY-3-(((3-(METHYLOXY)PHENYL)METHYL)AMINO)-1-(PHENYLMETHYL)PROPYL)-1-METHYL-1, 3,4,5-TETRAHYDRO-2,1-BENZOTHIAZEPINE-8-CARBOXAMIDE 2,2-DIOXIDE
2WF4A:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH 6-ETHYL-1-METHYL-N-((1S)-2-OXO-1-(PHENYLMETHYL)-3-(TETRAHYDRO-2H-PYRAN-4-YLAMINO)PROPYL)-1,3,4,6-TETRAHYDRO(1,2)THIAZEPINO(5,4,3-CD)INDOLE-8-CARBOXAMIDE 2,2-DIOXIDE
2WJOA:14-146; A:147-388HUMAN BACE (BETA SECRETASE) IN COMPLEX WITH CYCLOHEXANECARBOXYLIC ACID (2-(2-AM INO-6-PHENOXY-4H-QUINAZOLIN-3-YL)-2-CYCLOHEXYL-ETHYL)-AMIDE
2XFIA:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-((METHYLSULFONYL)(PHENYL)AMINO) BENZAMIDE
2XFJA:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-(2-OXO-1-PYRROLIDINYL)BENZAMIDE
2XFKA:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-((METHYLSULFONYL)( PHENYL)AMINO)BENZAMIDE
2ZDZA:76-208; A:209-446X-RAY STRUCTURE OF BACE-1 IN COMPLEX WITH COMPOUND 3.B.10
2ZE1A:76-208; A:209-446X-RAY STRUCTURE OF BACE-1 IN COMPLEX WITH COMPOUND 6G
2ZHRA:14-146; B:14-146; B:147-385; A:147-385CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH OM99-2 AT PH 5.0
2ZHSA:14-146; A:147-385CRYSTAL STRUCTURE OF BACE1 AT PH 4.0
2ZHTA:14-146; A:147-385CRYSTAL STRUCTURE OF BACE1 AT PH 4.5
2ZHUA:14-146; A:147-385CRYSTAL STRUCTURE OF BACE1 AT PH 5.0
2ZHVA:14-146; A:147-385CRYSTAL STRUCTURE OF BACE1 AT PH 7.0
2ZJHA:14-146; A:147-385CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-(1-BENZYL-PIPERIDIN-4-YL)-4-MERCAPTO-BUTYRAMIDE
2ZJIA:14-146; A:147-385CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(2,6-DIMETHOXY-BENZYL)-PIPERIDIN-4-YL]-4-MERCAPTO-BUTYRAMIDE
2ZJJA:14-146; A:147-385CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(4-FLUORO-BENZYL)-PIPERAZINE-2-CARBOXYLIC ACID (2-MERCAPTO-ETHYL)-AMIDE
2ZJKA:14-146; B:14-146; C:14-146; B:147-385; A:147-385; C:147-385CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(4-FLUORO-BENZYL)-PIPERAZINE-2-CARBOXYLIC ACID(3-MERCAPTO-PROPYL)-AMIDE
2ZJLA:14-146; A:147-385CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(5-BROMO-2,3-DIMETHOXY-BENZYL)-PIPERIDIN-4-YL]-4-MERCAPTO-BUTYRAMIDE
2ZJMA:14-146; A:147-385CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(5-CHLORO-2-ISOPROPOXY-3-METHOXY-BENZYL)-PIPERIDIN-4-YL]-2-(4-SULFAMOYL-PHENOXY)-ACETAMIDE
2ZJNA:14-146; A:147-385CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(5-CHLORO-2-ISOPROPOXY-3-METHOXY-BENZYL)-PIPERIDIN-4-YL]-2-(2-METHYL-4-SULFAMOYL-PHENOXY)-ACETAMIDE
3BRAA:14-146; A:147-386BACE-1 COMPLEXED WITH COMPOUND 1
3BUFA:14-146; A:147-386BACE-1 COMPLEXED WITH COMPOUND 2
3BUGA:14-146; A:147-386BACE-1 COMPLEXED WITH COMPOUND 3
3BUHA:14-146; A:147-386BACE-1 COMPLEXED WITH COMPOUND 4
3CIBA:75-207; B:75-207; B:208-446; A:208-447STRUCTURE OF BACE BOUND TO SCH727596
3CICA:75-207; B:75-207; B:208-446; A:208-447STRUCTURE OF BACE BOUND TO SCH709583
3CIDA:75-207; B:75-207; B:208-446; A:208-447STRUCTURE OF BACE BOUND TO SCH726222
3CKPA:14-146; B:14-146; C:14-146; C:147-386; A:147-386; B:147-386CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR
3CKRA:14-146; B:14-146; C:14-146; C:147-386; A:147-386; B:147-386CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR
3DM6A:14-146; B:14-146; C:14-146; C:147-385; B:147-385; A:147-385BETA-SECRETASE 1 COMPLEXED WITH STATINE-BASED INHIBITOR
3EXOA:14-146; A:147-385CRYSTAL STRUCTURE OF BACE1 BOUND TO INHIBITOR
3FKTA:34-166; A:167-403CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH SPIROPIPERDINE IMINOHYDANTOIN INHIBITOR
3GW5A:182-339; B:182-339; B:7-181; A:7-181CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH A NOVEL INHIBITOR
3H0BA:14-146; B:14-146; C:14-146; A:147-385; B:147-385; C:147-385DISCOVERY OF AMINOHETEROCYCLES AS A NOVEL BETA-SECRETASE INHIBITOR CLASS
3HVGA:14-146; B:14-146; C:14-146; B:147-385; C:147-385; A:147-385STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH EV0
3HW1A:14-146; C:14-146; B:14-146; A:147-385; B:147-385; C:147-385STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH LIGAND EV2
3I25A:14-146; A:147-385; B:147-385; C:147-385; B:14-146; C:14-146POTENT BETA-SECRETASE 1 HYDROXYETHYLENE INHIBITOR
3IGBA:76-208; A:209-447BACE-1 WITH COMPOUND 3
3IN3A:76-208; A:209-446BACE1 WITH COMPOUND 30
3IN4A:76-208; A:209-446BACE1 WITH COMPOUND 38
3INDA:76-208; A:209-448BACE1 WITH THE AMINOHYDANTOIN COMPOUND 29
3INEA:76-208; A:209-447BACE1 WITH THE AMINOHYDANTOIN COMPOUND S-34
3INFA:76-208; A:209-448BACE1 WITH THE AMINOHYDANTOIN COMPOUND 37
3INHA:76-208; A:209-448BACE1 WITH THE AMINOHYDANTOIN COMPOUND R-58
3IVHA:75-207; A:208-447DESIGN AND SYNTHESIS OF POTENT BACE-1 INHIBITORS WITH CELLULAR ACTIVITY: STRUCTURE-ACTIVITY RELATIONSHIP OF P1 SUBSTITUENTS
3IVIA:75-207; C:208-447; B:208-447; A:208-447; B:75-207; C:75-207DESIGN AND SYNTHESIS OF POTENT BACE-1 INHIBITORS WITH CELLULAR ACTIVITY: STRUCTURE-ACTIVITY RELATIONSHIP OF P1 SUBSTITUENTS
3IXJA:62-194; C:195-433; A:195-433; B:195-433; B:62-194; C:62-194CRYSTAL STRUCTURE OF BETA-SECRETASE 1 IN COMPLEX WITH SELECTIVE BETA-SECRETASE 1 INHIBITOR
3K5CA:14-146; A:147-385; B:147-385; C:147-385; B:14-146; C:14-146HUMAN BACE-1 COMPLEX WITH NB-216
3K5DA:14-146; B:14-146; C:14-146; A:147-385; B:147-385; C:147-386CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH AHM178
3K5FA:14-146; B:14-146; C:14-146; A:147-385; B:147-385; C:147-385HUMAN BACE-1 COMPLEX WITH AYH011
3K5GA:14-146; A:147-385; B:147-385; C:147-385; B:14-146; C:14-146HUMAN BACE-1 COMPLEX WITH BJC060
3KM4A:182-339; B:182-339; B:7-181; A:7-181OPTIMIZATION OF ORALLY BIOAVAILABLE ALKYL AMINE RENIN INHIBITORS
3KMXA:75-207; B:208-446; A:208-447; B:75-207STRUCTURE OF BACE BOUND TO SCH346572
3KMYA:75-207; B:208-446; A:208-447; B:75-207STRUCTURE OF BACE BOUND TO SCH12472
3KN0B:75-207; B:208-446; A:208-447; A:75-207STRUCTURE OF BACE BOUND TO SCH708236
3L38A:76-208; A:209-445BACE1 IN COMPLEX WITH THE AMINOPYRIDINE COMPOUND 44
3L3AA:76-208; A:209-446BACE-1 WITH THE AMINOPYRIDINE COMPOUND 32
3L58A:75-207; B:75-207; B:208-446; A:208-447STRUCTURE OF BACE BOUND TO SCH589432
3L59A:75-207; B:208-446; A:208-447; B:75-207STRUCTURE OF BACE BOUND TO SCH710413
3L5BA:75-207; B:75-207; B:208-446; A:208-447STRUCTURE OF BACE BOUND TO SCH713601
3L5CB:75-207; A:75-207; B:208-446; A:208-447STRUCTURE OF BACE BOUND TO SCH723871
3L5DB:75-207; A:75-207; B:208-446; A:208-447STRUCTURE OF BACE BOUND TO SCH723873
3L5EA:75-207; B:75-207; B:208-446; A:208-447STRUCTURE OF BACE BOUND TO SCH736062
3L5FA:75-207; B:75-207; B:208-446; A:208-447STRUCTURE OF BACE BOUND TO SCH736201
(-)
Human immunodeficiency virus 1 (1)
2QMPA:1-99; B:1-99CRYSTAL STRUCTURE OF HIV-1 PROTEASE COMPLEXED WITH PL-100
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. (1)
2JE4A:1-99; B:1-99ATOMIC-RESOLUTION CRYSTAL STRUCTURE OF CHEMICALLY-SYNTHESIZED HIV-1 PROTEASE IN COMPLEX WITH JG-365
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. (92)
1B6JA:1-99; B:101-199HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 1
1B6KA:1-99; B:101-199HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 5
1B6LA:1-99; B:101-199HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 4
1B6MA:1-99; B:101-199HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 6
1B6PA:1-99; B:101-199HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 7
1C6XA:1-99; B:201-299ALTERNATE BINDING SITE FOR THE P1-P3 GROUP OF A CLASS OF POTENT HIV-1 PROTEASE INHIBITORS AS A RESULT OF CONCERTED STRUCTURAL CHANGE IN 80'S LOOP.
1C6YA:1-99; B:201-299ALTERNATE BINDING SITE FOR THE P1-P3 GROUP OF A CLASS OF POTENT HIV-1 PROTEASE INHIBITORS AS A RESULT OF CONCERTED STRUCTURAL CHANGE IN 80'S LOOP.
1C6ZA:1-99; B:201-299ALTERNATE BINDING SITE FOR THE P1-P3 GROUP OF A CLASS OF POTENT HIV-1 PROTEASE INHIBITORS AS A RESULT OF CONCERTED STRUCTURAL CHANGE IN 80'S LOOP.
1C70A:1-99; B:201-299ALTERNATE BINDING SITE FOR THE P1-P3 GROUP OF A CLASS OF POTENT HIV-1 PROTEASE INHIBITORS AS A RESULT OF CONCERTED STRUCTURAL CHANGE IN 80'S LOOP.
1HBVA:1-99; B:1-99A CHECK ON RATIONAL DRUG DESIGN. CRYSTAL STRUCTURE OF A COMPLEX OF HIV-1 PROTEASE WITH A NOVEL GAMMA-TURN MIMETIC
1HSGA:1-99; B:1-99CRYSTAL STRUCTURE AT 1.9 ANGSTROMS RESOLUTION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) II PROTEASE COMPLEXED WITH L-735,524, AN ORALLY BIOAVAILABLE INHIBITOR OF THE HIV PROTEASES
1HSHA:1-99; B:1-99; C:1-99; D:1-99CRYSTAL STRUCTURE AT 1.9 ANGSTROMS RESOLUTION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) II PROTEASE COMPLEXED WITH L-735,524, AN ORALLY BIOAVAILABLE INHIBITOR OF THE HIV PROTEASES
1HVCA:1A-99A; A:1B-99BCRYSTAL STRUCTURE OF A TETHERED DIMER OF HIV-1 PROTEASE COMPLEXED WITH AN INHIBITOR
1K6CA:1-99; B:1-99LACK OF SYNERGY FOR INHIBITORS TARGETING A MULTI-DRUG RESISTANT HIV-1 PROTEASE
1K6PA:1-99; B:1-99LACK OF SYNERGY FOR INHIBITORS TARGETING A MULTI-DRUG RESISTANT HIV-1 PROTEASE
1K6TA:1-99; B:1-99LACK OF SYNERGY FOR INHIBITORS TARGETING A MULTI-DRUG RESISTANT HIV-1 PROTEASE
1K6VA:1-99; B:1-99LACK OF SYNERGY FOR INHIBITORS TARGETING A MULTI-DRUG RESISTANT HIV-1 PROTEASE
1KJ4A:1-99; B:1-99; C:1-99; D:1-99SUBSTRATE SHAPE DETERMINES SPECIFICITY OF RECOGNITION RECOGNITION FOR HIV-1 PROTEASE: ANALYSIS OF CRYSTAL STRUCTURES OF SIX SUBSTRATE COMPLEXES
1KJ7A:1-99; B:1-99SUBSTRATE SHAPE DETERMINES SPECIFICITY OF RECOGNITION RECOGNITION FOR HIV-1 PROTEASE: ANALYSIS OF CRYSTAL STRUCTURES OF SIX SUBSTRATE COMPLEXES
1KJFA:1-99; B:1-99SUBSTRATE SHAPE DETERMINES SPECIFICITY OF RECOGNITION RECOGNITION FOR HIV-1 PROTEASE: ANALYSIS OF CRYSTAL STRUCTURES OF SIX SUBSTRATE COMPLEXES
1KJGA:1-99; B:1-99SUBSTRATE SHAPE DETERMINES SPECIFICITY OF RECOGNITION RECOGNITION FOR HIV-1 PROTEASE: ANALYSIS OF CRYSTAL STRUCTURES OF SIX SUBSTRATE COMPLEXES
1KJHA:1-99; B:1-99SUBSTRATE SHAPE DETERMINES SPECIFICITY OF RECOGNITION RECOGNITION FOR HIV-1 PROTEASE: ANALYSIS OF CRYSTAL STRUCTURES OF SIX SUBSTRATE COMPLEXES
1N49A:1-99; B:1-99; C:1-99; D:1-99VIABILITY OF A DRUG-RESISTANT HIV-1 PROTEASE VARIANT: STRUCTURAL INSIGHTS FOR BETTER ANTI-VIRAL THERAPY
1NPAA:1-99; B:1-99CRYSTAL STRUCTURE OF HIV-1 PROTEASE-HUP
1NPVA:1-99; B:201-299CRYSTAL STRUCTURE OF HIV-1 PROTEASE COMPLEXED WITH LDC271
1NPWA:1-99; B:201-299CRYSTAL STRUCTURE OF HIV PROTEASE COMPLEXED WITH LGZ479
1ODWA:1-99; B:1-99NATIVE HIV-1 PROTEINASE
1ODXA:1-99; B:1-99HIV-1 PROTEINASE MUTANT A71T, V82A
1RL8A:1-99; B:1-99CRYSTAL STRUCTURE OF THE COMPLEX OF RESISTANT STRAIN OF HIV-1 PROTEASE(V82A MUTANT) WITH RITONAVIR
1RPIA:1-99; B:1-99CRYSTAL STRUCTURES OF A MULTIDRUG-RESISTANT HIV-1 PROTEASE REVEAL AN EXPANDED ACTIVE SITE CAVITY
1RQ9A:1-99; B:1-99CRYSTAL STRUCTURES OF A MULTIDRUG-RESISTANT HIV-1 PROTEASE REVEAL AN EXPANDED ACTIVE SITE CAVITY
1RV7A:1-99; B:1-99CRYSTAL STRUCTURES OF A MULTIDRUG-RESISTANT HIV-1 PROTEASE REVEAL AN EXPANDED ACTIVE SITE CAVITY
1SDTA:1-99; B:101-199CRYSTAL STRUCTURES OF HIV PROTEASE V82A AND L90M MUTANTS REVEAL CHANGES IN INDINAVIR BINDING SITE.
1SDUA:1-99; B:101-199CRYSTAL STRUCTURES OF HIV PROTEASE V82A AND L90M MUTANTS REVEAL CHANGES IN INDINAVIR BINDING SITE.
1SDVA:1-99; B:101-199CRYSTAL STRUCTURES OF HIV PROTEASE V82A AND L90M MUTANTS REVEAL CHANGES IN INDINAVIR BINDING SITE.
1SP5A:1-99; B:1-99CRYSTAL STRUCTURE OF HIV-1 PROTEASE COMPLEXED WITH A PRODUCT OF AUTOPROTEOLYSIS
1T3RA:1-99; B:1-99HIV PROTEASE WILD-TYPE IN COMPLEX WITH TMC114 INHIBITOR
1T7IA:1-99; B:1-99THE STRUCTURAL AND THERMODYNAMIC BASIS FOR THE BINDING OF TMC114, A NEXT-GENERATION HIV-1 PROTEASE INHIBITOR.
1T7JA:1-99; B:1-99CRYSTAL STRUCTURE OF INHIBITOR AMPRENAVIR IN COMPLEX WITH A MULTI-DRUG RESISTANT VARIANT OF HIV-1 PROTEASE (L63P/V82T/I84V)
1T7KA:1-99; B:1-99CRYSTAL STRUCTURE OF HIV PROTEASE COMPLEXED WITH ARYLSULFONAMIDE AZACYCLIC UREA
1TCXA:1-99; B:1-99HIV TRIPLE MUTANT PROTEASE COMPLEXED WITH INHIBITOR SB203386
1TW7A:1-99; B:1-99WIDE OPEN 1.3A STRUCTURE OF A MULTI-DRUG RESISTANT HIV-1 PROTEASE REPRESENTS A NOVEL DRUG TARGET
1U8GA:1-99; B:1-99CRYSTAL STRUCTURE OF A HIV-1 PROTEASE IN COMPLEX WITH PEPTIDOMIMETIC INHIBITOR KI2-PHE-GLU-GLU-NH2
1XL2A:1-99; B:1-99HIV-1 PROTEASE IN COMPLEX WITH PYRROLIDINMETHANAMINE
1XL5A:1-99; B:1-99HIV-1 PROTEASE IN COMPLEX WITH AMIDHYROXYSULFONE
1YT9A:1-99; B:1-99HIV PROTEASE WITH OXIMINOARYLSULFONAMIDE BOUND
1ZTZA:1-99; B:1-99CRYSTAL STRUCTURE OF HIV PROTEASE- METALLACARBORANE COMPLEX
2A1EA:1-99; B:1-99HIGH RESOLUTION STRUCTURE OF HIV-1 PR WITH TS-126
2A4FA:1-99; B:1-99SYNTHESIS AND ACTIVITY OF N-AXYL AZACYCLIC UREA HIV-1 PROTEASE INHIBITORS WITH HIGH POTENCY AGAINST MULTIPLE DRUG RESISTANT VIRAL STRAINS.
2AOFA:1-99; B:101-199CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE MUTANT V82A WITH A SUBSTRATE ANALOG P1-P6
2AVOA:1-99; B:1-99KINETICS, STABILITY, AND STRUCTURAL CHANGES IN HIGH RESOLUTION CRYSTAL STRUCTURES OF HIV-1 PROTEASE WITH DRUG RESISTANT MUTATIONS L24I, I50V, AND G73S
2AVSA:1-99; B:1-99KINETICS, STABILITY, AND STRUCTURAL CHANGES IN HIGH RESOLUTION CRYSTAL STRUCTURES OF HIV-1 PROTEASE WITH DRUG RESISTANT MUTATIONS L24I, I50V, AND G73S
2AVVA:1-99; B:1-99; D:1-99; E:1-99KINETICS, STABILITY, AND STRUCTURAL CHANGES IN HIGH RESOLUTION CRYSTAL STRUCTURES OF HIV-1 PROTEASE WITH DRUG RESISTANT MUTATIONS L24I, I50V, AND G73S
2BB9A:1-99; B:201-299STRUCTURE OF HIV1 PROTEASE AND AKC4P_133A COMPLEX.
2BBBA:1-99; B:201-299STRUCTURE OF HIV1 PROTEASE AND HH1_173_3A COMPLEX.
2BPVA:1-99; B:1-99HIV-1 PROTEASE-INHIBITOR COMPLEX
2BPWA:1-99; B:1-99HIV-1 PROTEASE-INHIBITOR COMPLEX
2BPXA:1-99; B:1-99HIV-1 PROTEASE-INHIBITOR COMPLEX
2BPYA:1-99; B:1-99HIV-1 PROTEASE-INHIBITOR COMPLEX
2BPZA:1-99; B:1-99HIV-1 PROTEASE-INHIBITOR COMPLEX
2FXDA:1-99; B:1-99X-RAY CRYSTAL STRUCTURE OF HIV-1 PROTEASE IRM MUTANT COMPLEXED WITH ATAZANAVIR (BMS-232632)
2FXEA:1-99; B:1-99X-RAY CRYSTAL STRUCTURE OF HIV-1 PROTEASE CRM MUTANT COMPLEXED WITH ATAZANAVIR (BMS-232632)
2HB3A:1-99; B:1-99WILD-TYPE HIV-1 PROTEASE IN COMPLEX WITH POTENT INHIBITOR GRL06579
2HS1A:1-99; B:101-199ULTRA-HIGH RESOLUTION X-RAY CRYSTAL STRUCTURE OF HIV-1 PROTEASE V32I MUTANT WITH TMC114 (DARUNAVIR) INHIBITOR
2HS2A:1-99; B:101-199CRYSTAL STRUCTURE OF M46L MUTANT OF HIV-1 PROTEASE COMPLEXED WITH TMC114 (DARUNAVIR)
2I4DA:1-99; B:201-299CRYSTAL STRUCTURE OF WT HIV-1 PROTEASE WITH GS-8373
2I4UA:1-99; B:201-299HIV-1 PROTEASE WITH TMC-126
2I4VA:1-99; B:201-299HIV-1 PROTEASE I84V, L90M WITH TMC126
2I4WA:1-99; B:201-299HIV-1 PROTEASE WT WITH GS-8374
2I4XA:1-99; B:201-299HIV-1 PROTEASE I84V, L90M WITH GS-8374
2IDWA:1-99; B:101-199CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE MUTANT V82A WITH A POTENT NON-PEPTIDE INHIBITOR (UIC-94017)
2IENA:1-99; B:101-199CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE WITH A POTENT NON-PEPTIDE INHIBITOR (UIC-94017)
2IEOA:1-99; B:101-199CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE MUTANT I84V WITH A POTENT NON-PEPTIDE INHIBITOR (UIC-94017)
2NMW  [entry was replaced by entry 3OXC without any CATH domain information]
2NMYA:1-99; B:101-199CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE MUTANT V82A WITH A INHIBITOR SAQUINAVIR
2NMZA:1-99; B:101-199CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE MUTANT V82A WITH A INHIBITOR SAQUINAVIR
2NNKA:1-99; B:101-199CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE MUTANT I84V WITH A INHIBITOR SAQUINAVIR
2NNPA:1-99; B:101-199CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE MUTANT I84V WITH A INHIBITOR SAQUINAVIR
2NPHA:1-99; B:1001-1099CRYSTAL STRUCTURE OF HIV1 PROTEASE IN SITU PRODUCT COMPLEX
2P3AA:1-99; B:1-99CRYSTAL STRUCTURE OF THE MULTI-DRUG RESISTANT MUTANT SUBTYPE B HIV PROTEASE COMPLEXED WITH TL-3 INHIBITOR
2P3BA:1-99; B:1-99CRYSTAL STRUCTURE OF THE SUBTYPE B WILD TYPE HIV PROTEASE COMPLEXED WITH TL-3 INHIBITOR
2P3CA:1-99; B:1-99CRYSTAL STRUCTURE OF THE SUBTYPE F WILD TYPE HIV PROTEASE COMPLEXED WITH TL-3 INHIBITOR
2PQZA:1-99; B:1-99HIV-1 PROTEASE IN COMPLEX WITH A PYRROLIDINE-BASED INHIBITOR
2ZYEA:1-99; B:101-199STRUCTURE OF HIV-1 PROTEASE IN COMPLEX WITH POTENT INHIBITOR KNI-272 DETERMINED BY NEUTRON CRYSTALLOGRAPHY
3A2OA:1-99; B:101-199CRYSTAL STRUCTURE OF HIV-1 PROTEASE COMPLEXED WITH KNI-1689
3BVAA:1-99; B:1-99CYSTAL STRUCTURE OF HIV-1 ACTIVE SITE MUTANT D25N AND P2-NC ANALOG INHIBITOR
3BVBA:1-99; B:1-99CYSTAL STRUCTURE OF HIV-1 ACTIVE SITE MUTANT D25N AND INHIBITOR DARUNAVIR
3CYXA:1-99; B:1-99CRYSTAL STRUCTURE OF HIV-1 MUTANT I50V AND INHIBITOR SAQUINAVIRA
3FX5A:1-99; B:101-199STRUCTURE OF HIV-1 PROTEASE IN COMPLEX WITH POTENT INHIBITOR KNI-272 DETERMINED BY HIGH RESOLUTION X-RAY CRYSTALLOGRAPHY
3GGAA:1-99; B:1-99; C:1-99; D:1-99; G:1-99; H:1-99HIV PROTEASE INHIBITORS WITH PSEUDO-SYMMETRIC CORES
3GGVA:1-99; B:1-99; C:1-99; D:1-99; E:1-99; F:1-99; G:1-99; H:1-99; I:1-99HIV PROTEASE, PSEUDO-SYMMETRIC INHIBITORS
3GGXA:1-99; F:1-99; G:1-99; H:1-99; B:1-99; C:1-99; D:1-99; E:1-99HIV PROTEASE, PSEUDO-SYMMETRIC INHIBITORS
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. (108)
1A8GA:1-99; B:1-99HIV-1 PROTEASE IN COMPLEX WITH SDZ283-910
1A8KA:1-99; B:1-99; D:1-99; E:1-99CRYSTALLOGRAPHIC ANALYSIS OF HUMAN IMMUNODEFICIENCY VIRUS 1 PROTEASE WITH AN ANALOG OF THE CONSERVED CA-P2 SUBSTRATE: INTERACTIONS WITH FREQUENTLY OCCURRING GLUTAMIC ACID RESIDUE AT P2' POSITION OF SUBSTRATES
1A94A:1-99; B:1-99; D:1-99; E:1-99STRUCTURAL BASIS FOR SPECIFICITY OF RETROVIRAL PROTEASES
1A9MA:1-99; B:1-99G48H MUTANT OF HIV-1 PROTEASE IN COMPLEX WITH A PEPTIDIC INHIBITOR U-89360E
1AAQA:1-99; B:1-99HYDROXYETHYLENE ISOSTERE INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS-1 PROTEASE: STRUCTURE-ACTIVITY ANALYSIS USING ENZYME KINETICS, X-RAY CRYSTALLOGRAPHY, AND INFECTED T-CELL ASSAYS
1AXAA:1-99; B:1-99ACTIVE-SITE MOBILITY IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE AS DEMONSTRATED BY CRYSTAL STRUCTURE OF A28S MUTANT
1D4SA:1-99; B:1-99HIV-1 PROTEASE V82F/I84V DOUBLE MUTANT/TIPRANAVIR COMPLEX
1D4YA:1-99; B:1-99HIV-1 PROTEASE TRIPLE MUTANT/TIPRANAVIR COMPLEX
1DAZC:1-99; D:101-199STRUCTURAL AND KINETIC ANALYSIS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE
1DIFA:1-99; B:1-99HIV-1 PROTEASE IN COMPLEX WITH A DIFLUOROKETONE CONTAINING INHIBITOR A79285
1DW6C:1-99; D:101-199STRUCTURAL AND KINETIC ANALYSIS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE
1EBKC:1-99; D:101-199; E:1-99; F:101-199STRUCTURAL AND KINETIC ANALYSIS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE
1EBWA:1-99; B:101-199HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA322
1EBYA:1-99; B:101-199HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA369
1EBZA:1-99; B:101-199HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA388
1EC0A:1-99; B:101-199HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA403
1EC1A:1-99; B:101-199HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA409
1EC2A:1-99; B:101-199HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA428
1EC3A:1-99; B:101-199HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR MSA367
1F7AA:1-99; B:1-99HOW DOES A SYMMETRIC DIMER RECOGNIZE AN ASYMMETRIC SUBSTRATE? A SUBSTRATE COMPLEX OF HIV-1 PROTEASE.
1FB7A:1-99CRYSTAL STRUCTURE OF AN IN VIVO HIV-1 PROTEASE MUTANT IN COMPLEX WITH SAQUINAVIR: INSIGHTS INTO THE MECHANISMS OF DRUG RESISTANCE
1FEJC:1-99; D:101-199STRUCTURAL IMPLICATIONS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE: HIGH RESOLUTION CRYSTAL STRUCTURES OF THE MUTANT PROTEASE/SUBSTRATE ANALOG COMPLEXES
1FF0C:1-99; D:101-199STRUCTURAL IMPLICATIONS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE: HIGH RESOLUTION CRYSTAL STRUCTURES OF THE MUTANT PROTEASE/SUBSTRATE ANALOG COMPLEXES.
1FFFC:1-99; D:101-199STRUCTURAL IMPLICATIONS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE : HIGH RESOLUTION CRYSTAL STRUCTURES OF THE MUTANT PROTEASE/SUBSTRATE ANALOG COMPLEXES.
1FFIC:1-99; D:101-199STRUCTURAL IMPLICATIONS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE: HIGH RESOLUTION CRYSTAL STRUCTURES OF THE MUTANT PROTEASE/SUBSTRATE ANALOG COMPLEXES
1FG6C:1-99; D:101-199STRUCTURAL IMPLICATIONS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE: HIGH RESOLUTION CRYSTAL STRUCTURES OF THE MUTANT PROTEASE/SUBSTRATE ANALOG COMPLEXES
1FG8C:1-99; D:101-199STRUCTURAL IMPLICATIONS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE: HIGH RESOLUTION CRYSTAL STRUCTURES OF THE MUTANT PROTEASE/SUBSTRATE ANALOG COMPLEXES
1FGCC:1-99; D:101-199STRUCTURAL IMPLICATIONS OF DRUG RESISTANT MUTANTS OF HIV-1 PROTEASE: HIGH RESOLUTION CRYSTAL STRUCTURES OF THE MUTANT PROTEASE/SUBSTRATE ANALOG COMPLEXES
1FQXA:1-99; B:1-99CRYSTAL STRUCTURE OF THE COMPLEX OF HIV-1 PROTEASE WITH A PEPTIDOMIMETIC INHIBITOR
1G6LA:1-99; A:1001-10991.9A CRYSTAL STRUCTURE OF TETHERED HIV-1 PROTEASE
1GNMA:1-99; B:1-99HIV-1 PROTEASE MUTANT WITH VAL 82 REPLACED BY ASP (V82D) COMPLEXED WITH U89360E (INHIBITOR)
1GNNA:1-99; B:1-99HIV-1 PROTEASE MUTANT WITH VAL 82 REPLACED BY ASN (V82N) COMPLEXED WITH U89360E (INHIBITOR)
1GNOA:1-99; B:1-99HIV-1 PROTEASE (WILD TYPE) COMPLEXED WITH U89360E (INHIBITOR)
1HEFE:1-99THE CRYSTAL STRUCTURES AT 2.2 ANGSTROMS RESOLUTION OF HYDROXYETHYLENE-BASED INHIBITORS BOUND TO HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE SHOW THAT THE INHIBITORS ARE PRESENT IN TWO DISTINCT ORIENTATIONS
1HEGE:1-99THE CRYSTAL STRUCTURES AT 2.2 ANGSTROMS RESOLUTION OF HYDROXYETHYLENE-BASED INHIBITORS BOUND TO HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE SHOW THAT THE INHIBITORS ARE PRESENT IN TWO DISTINCT ORIENTATIONS
1HIVA:1-99; B:1-99CRYSTAL STRUCTURE OF A COMPLEX OF HIV-1 PROTEASE WITH A DIHYDROETHYLENE-CONTAINING INHIBITOR: COMPARISONS WITH MOLECULAR MODELING
1HOSA:1-99; B:1-99INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS-1 PROTEASE BY A C2-SYMMETRIC PHOSPHINATE SYNTHESIS AND CRYSTALLOGRAPHIC ANALYSIS
1HPOA:1-99; B:1-99HIV-1 PROTEASE TRIPLE MUTANT/U103265 COMPLEX
1HPSA:1-99; B:1-99RATIONAL DESIGN, SYNTHESIS AND CRYSTALLOGRAPHIC ANALYSIS OF A HYDROXYETHYLENE-BASED HIV-1 PROTEASE INHIBITOR CONTAINING A HETEROCYCLIC P1'-P2' AMIDE BOND ISOSTERE
1HPVA:1-99; B:1-99CRYSTAL STRUCTURE OF HIV-1 PROTEASE IN COMPLEX WITH VX-478, A POTENT AND ORALLY BIOAVAILABLE INHIBITOR OF THE ENZYME
1HTEA:1-99; B:1-99X-RAY CRYSTALLOGRAPHIC STUDIES OF A SERIES OF PENICILLIN-DERIVED ASYMMETRIC INHIBITORS OF HIV-1 PROTEASE
1HTFA:1-99; B:1-99X-RAY CRYSTALLOGRAPHIC STUDIES OF A SERIES OF PENICILLIN-DERIVED ASYMMETRIC INHIBITORS OF HIV-1 PROTEASE
1HTGA:1-99; B:1-99X-RAY CRYSTALLOGRAPHIC STUDIES OF A SERIES OF PENICILLIN-DERIVED ASYMMETRIC INHIBITORS OF HIV-1 PROTEASE
1HVIA:1-99; B:1-99INFLUENCE OF STEREOCHEMISTRY ON ACTIVITY AND BINDING MODES FOR C2 SYMMETRY-BASED DIOL INHIBITORS OF HIV-1 PROTEASE
1HVJA:1-99; B:1-99INFLUENCE OF STEREOCHEMISTRY ON ACTIVITY AND BINDING MODES FOR C2 SYMMETRY-BASED DIOL INHIBITORS OF HIV-1 PROTEASE
1HVKA:1-99; B:1-99INFLUENCE OF STEREOCHEMISTRY ON ACTIVITY AND BINDING MODES FOR C2 SYMMETRY-BASED DIOL INHIBITORS OF HIV-1 PROTEASE
1HVLA:1-99; B:1-99INFLUENCE OF STEREOCHEMISTRY ON ACTIVITY AND BINDING MODES FOR C2 SYMMETRY-BASED DIOL INHIBITORS OF HIV-1 PROTEASE
1HVRA:1-99; B:1-99RATIONAL DESIGN OF POTENT, BIOAVAILABLE, NONPEPTIDE CYCLIC UREAS AS HIV PROTEASE INHIBITORS
1HVSA:1-99; B:1-99STRUCTURAL BASIS OF DRUG RESISTANCE FOR THE V82A MUTANT OF HIV-1 PROTEASE: BACKBONE FLEXIBILITY AND SUBSITE REPACKING
1HXWA:1-99; B:1-99HIV-1 PROTEASE DIMER COMPLEXED WITH A-84538
1IIQA:1-99; B:1-99CRYSTAL STRUCTURE OF HIV-1 PROTEASE COMPLEXED WITH A HYDROXYETHYLAMINE PEPTIDOMIMETIC INHIBITOR
1IZHA:1-99; B:1-99INHIBITOR OF HIV PROTEASE WITH UNUSUAL BINDING MODE POTENTLY INHIBITING MULTI-RESISTANT PROTEASE MUTANTS
1IZIA:1-99; B:1-99INHIBITOR OF HIV PROTEASE WITH UNUSUAL BINDING MODE POTENTLY INHIBITING MULTI-RESISTANT PROTEASE MUTANTS
1K1TA:1-99; B:101-199COMBINING MUTATIONS IN HIV-1 PROTEASE TO UNDERSTAND MECHANISMS OF RESISTANCE
1K1UA:1-99; B:101-199COMBINING MUTATIONS IN HIV-1 PROTEASE TO UNDERSTAND MECHANISMS OF RESISTANCE
1K2BA:1-99; B:1-99COMBINING MUTATIONS IN HIV-1 PROTEASE TO UNDERSTAND MECHANISMS OF RESISTANCE
1K2CA:1-99; B:1-99COMBINING MUTATIONS IN HIV-1 PROTEASE TO UNDERSTAND MECHANISMS OF RESISTANCE
1LV1A:1-99; A:1001-1099CRYSTAL STRUCTURE ANALYSIS OF THE NON-ACTIVE SITE MUTANT OF TETHERED HIV-1 PROTEASE TO 2.1A RESOLUTION
1LZQA:1-99; B:101-199CRYSTAL STRUCTURE OF THE COMPLEX OF MUTANT HIV-1 PROTEASE (A71V, V82T, I84V) WITH AN ETHYLENAMINE PEPTIDOMIMETIC INHIBITOR BOC-PHE-PSI[CH2CH2NH]-PHE-GLU-PHE-NH2
1M0BA:1-99; B:101-199HIV-1 PROTEASE IN COMPLEX WITH AN ETHYLENEAMINE INHIBITOR
1MRWA:1-99; B:1-99STRUCTURE OF HIV PROTEASE (MUTANT Q7K L33I L63I) COMPLEXED WITH KNI-577
1MRXA:1-99; B:1-99STRUCTURE OF HIV PROTEASE (MUTANT Q7K L33I L63I V82F I84V ) COMPLEXED WITH KNI-577
1MSMA:1-99; B:1-99THE HIV PROTEASE (MUTANT Q7K L33I L63I) COMPLEXED WITH KNI-764 (AN INHIBITOR)
1MSNA:1-99; B:1-99THE HIV PROTEASE (MUTANT Q7K L33I L63I V82F I84V) COMPLEXED WITH KNI-764 (AN INHIBITOR)
1MT7A:1-99; B:1-99VIABILITY OF A DRUG-RESISTANT HIV-1 PROTEASE MUTANT: STRUCTURAL INSIGHTS FOR BETTER ANTIVIRAL THERAPY
1MT8A:1-99; B:1-99VIABILITY OF A DRUG-RESISTANT HIV-1 PROTEASE MUTANT: STRUCTURAL INSIGHTS FOR BETTER ANTIVIRAL THERAPY
1MT9A:1-99; B:1-99VIABILITY OF A DRUG-RESISTANT HIV-1 PROTEASE MUTANT: STRUCTURAL INSIGHTS FOR BETTER ANTIVIRAL THERAPY
1MTBA:1-99; B:1-99VIABILITY OF A DRUG-RESISTANT HIV-1 PROTEASE MUTANT: STRUCTURAL INSIGHTS FOR BETTER ANTIVIRAL THERAPY
1MTRA:1-99; B:1-99HIV-1 PROTEASE COMPLEXED WITH A CYCLIC PHE-ILE-VAL PEPTIDOMIMETIC INHIBITOR
1MUIA:1-99; B:1-99CRYSTAL STRUCTURE OF HIV-1 PROTEASE COMPLEXED WITH LOPINAVIR.
1NH0A:1-99; B:1-991.03 A STRUCTURE OF HIV-1 PROTEASE: INHIBITOR BINDING INSIDE AND OUTSIDE THE ACTIVE SITE
1OHRA:1-99; B:1-99VIRACEPT (R) (NELFINAVIR MESYLATE, AG1343): A POTENT ORALLY BIOAVAILABLE INHIBITOR OF HIV-1 PROTEASE
1SGUA:1-99; B:1-99COMPARING THE ACCUMULATION OF ACTIVE SITE AND NON-ACTIVE SITE MUTATIONS IN THE HIV-1 PROTEASE
1SH9A:1-99; B:1-99COMPARING THE ACCUMULATION OF ACTIVE SITE AND NON-ACTIVE SITE MUTATIONS IN THE HIV-1 PROTEASE
1VIJA:1-99; B:1-99HIV-1 PROTEASE COMPLEXED WITH THE INHIBITOR HOE/BAY 793 HEXAGONAL FORM
1VIKA:1-99; B:1-99HIV-1 PROTEASE COMPLEXED WITH THE INHIBITOR HOE/BAY 793 ORTHORHOMBIC FORM
1WBKA:1-99; B:1-99HIV-1 PROTEASE IN COMPLEX WITH ASYMMETRIC INHIBITOR, BEA568
1WBMA:1-99; B:1-99HIV-1 PROTEASE IN COMPLEX WITH SYMMETRIC INHIBITOR, BEA450
1Z8CA:1-99; B:101-199CRYSTAL STRUCTURE OF THE COMPLEX OF MUTANT HIV-1 PROTEASE (L63P, A71V, V82T, I84V) WITH A HYDROXYETHYLAMINE PEPTIDOMIMETIC INHIBITOR BOC-PHE-PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2
1ZBGA:1-99; B:101-199CRYSTAL STRUCTURE OF A COMPLEX OF MUTANT HIV-1 PROTEASE (A71V, V82T, I84V) WITH A HYDROXYETHYLAMINE PEPTIDOMIMETIC INHIBITOR BOC-PHE-PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2
1ZJ7A:1-99CRYSTAL STRUCTURE OF A COMPLEX OF MUTANT HIV-1 PROTEASE (A71V, V82T, I84V) WITH A HYDROXYETHYLAMINE PEPTIDOMIMETIC INHIBITOR BOC-PHE-PSI[S-CH(OH)CH2NH]-PHE-GLU-PHE-NH2
1ZLFA:1-99; B:101-199CRYSTAL STRUCTURE OF A COMPLEX OF MUTANT HIV-1 PROTEASE (A71V, V82T, I84V) WITH A HYDROXYETHYLAMINE PEPTIDOMIMETIC INHIBITOR
1ZP8A:1-99HIV PROTEASE WITH INHIBITOR AB-2
1ZPAA:1-99HIV PROTEASE WITH SCRIPPS AB-3 INHIBITOR
1ZPKA:1-99; B:101-199CRYSTAL STRUCTURE OF THE COMPLEX OF MUTANT HIV-1 PROTEASE (A71V, V82T, I84V) WITH A HYDROXYETHYLAMINE PEPTIDOMIMETIC INHIBITOR BOC-PHE-PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2
1ZSFA:1-99; B:101-199CRYSTAL STRUCTURE OF COMPLEX OF A HYDROXYETHYLAMINE INHIBITOR WITH HIV-1 PROTEASE AT 2.0A RESOLUTION
1ZSRA:1-99; B:101-199CRYSTAL STRUCTURE OF WILD TYPE HIV-1 PROTEASE (BRU ISOLATE) WITH A HYDROXYETHYLAMINE PEPTIDOMIMETIC INHIBITOR BOC-PHE-PSI[S-CH(OH) CH2NH]-PHE-GLU-PHE-NH2
2AQUA:1-99; B:1-99STRUCTURE OF HIV-1 PROTEASE BOUND TO ATAZANAVIR
2B60A:1-99; B:1-99STRUCTURE OF HIV-1 PROTEASE MUTANT BOUND TO RITONAVIR
2B7ZA:1-99; B:1-99STRUCTURE OF HIV-1 PROTEASE MUTANT BOUND TO INDINAVIR
2FDDA:1-99; B:1-99CRYSTAL STRUCTURE OF HIV PROTEASE D545701 BOUND WITH GW0385
2FDEA:1-99; B:1-99WILD TYPE HIV PROTEASE BOUND WITH GW0385
2FLEA:1-99; B:1-99STRUCTURAL ANALYSIS OF ASYMMETRIC INHIBITOR BOUND TO THE HIV-1 PROTEASE V82A MUTANT
2G69A:1-99STRUCTURE OF UNLIGANDED HIV-1 PROTEASE F53L MUTANT
2P3DA:1-99; B:1-99CRYSTAL STRUCTURE OF THE MULTI-DRUG RESISTANT MUTANT SUBTYPE F HIV PROTEASE COMPLEXED WITH TL-3 INHIBITOR
2QCIA:1-99; B:101-199HIV-1 PROTEASE MUTANT D30N WITH POTENT ANTIVIRAL INHIBITOR GRL-98065
2QD6A:1-99; B:101-199HIV-1 PROTEASE MUTANT I50V WITH POTENT ANTIVIRAL INHIBITOR GRL-98065
2QD7A:1-99; B:101-199HIV-1 PROTEASE MUTANT V82A WITH POTENT ANTIVIRAL INHIBITOR GRL-98065
2QD8A:1-99; B:101-199HIV-1 PROTEASE MUTANT I84V WITH POTENT ANTIVIRAL INHIBITOR GRL-98065
2WHHA:1-99; A:1001-1099HIV-1 PROTEASE TETHERED DIMER Q-PRODUCT COMPLEX ALONG WITH NUCLEOPHILIC WATER MOLECULE
2Z4OA:1-99; B:101-199WILD TYPE HIV-1 PROTEASE WITH POTENT ANTIVIRAL INHIBITOR GRL-98065
3HVPA:1-99CONSERVED FOLDING IN RETROVIRAL PROTEASES. CRYSTAL STRUCTURE OF A SYNTHETIC HIV-1 PROTEASE
4HVPA:1-99; B:1-99STRUCTURE OF COMPLEX OF SYNTHETIC HIV-1 PROTEASE WITH A SUBSTRATE-BASED INHIBITOR AT 2.3 ANGSTROMS RESOLUTION
4PHVA:1-99; B:1-99X-RAY CRYSTAL STRUCTURE OF THE HIV PROTEASE COMPLEX WITH L-700,417, AN INHIBITOR WITH PSEUDO C2 SYMMETRY
5HVPA:1-99; B:201-299CRYSTALLOGRAPHIC ANALYSIS OF A COMPLEX BETWEEN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE AND ACETYL-PEPSTATIN AT 2.0-ANGSTROMS RESOLUTION
7HVPA:1-99; B:1-99X-RAY CRYSTALLOGRAPHIC STRUCTURE OF A COMPLEX BETWEEN A SYNTHETIC PROTEASE OF HUMAN IMMUNODEFICIENCY VIRUS 1 AND A SUBSTRATE-BASED HYDROXYETHYLAMINE INHIBITOR
8HVPA:1-99; B:1-99STRUCTURE AT 2.5-ANGSTROMS RESOLUTION OF CHEMICALLY SYNTHESIZED HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE COMPLEXED WITH A HYDROXYETHYLENE*-BASED INHIBITOR
9HVPA:1-99; B:1-99DESIGN, ACTIVITY AND 2.8 ANGSTROMS CRYSTAL STRUCTURE OF A C2 SYMMETRIC INHIBITOR COMPLEXED TO HIV-1 PROTEASE
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Cell_line: s2. (1)
1HIHA:1-99; B:1-99COMPARATIVE ANALYSIS OF THE X-RAY STRUCTURES OF HIV-1 AND HIV-2 PROTEASES IN COMPLEX WITH CGP 53820, A NOVEL PSEUDOSYMMETRIC INHIBITOR
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Human immunodeficiency virus 1. Organism_taxid: 11676. (1)
2J9JA:1-99; B:1-99ATOMIC-RESOLUTION CRYSTAL STRUCTURE OF CHEMICALLY-SYNTHESIZED HIV-1 PROTEASE COMPLEXED WITH INHIBITOR JG-365
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Strain: bh10. (1)
2PC0A:1001-1099APO WILD-TYPE HIV PROTEASE IN THE OPEN CONFORMATION
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Strain: bh10. Cell_line: bl21. (2)
1AJVA:1-99; B:1-99HIV-1 PROTEASE IN COMPLEX WITH THE CYCLIC SULFAMIDE INHIBITOR AHA006
1AJXA:1-99; B:1-99HIV-1 PROTEASE IN COMPLEX WITH THE CYCLIC UREA INHIBITOR AHA001
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Strain: bh102 isolate. (5)
1DMPA:1-99; B:1-99STRUCTURE OF HIV-1 PROTEASE COMPLEX
1MERA:1-99; B:1-99HIV-1 MUTANT (I84V) PROTEASE COMPLEXED WITH DMP450
1MESA:1-99; B:1-99HIV-1 MUTANT (I84V) PROTEASE COMPLEXED WITH DMP323
1META:1-99; B:1-99HIV-1 MUTANT (V82F) PROTEASE COMPLEXED WITH DMP323
1MEUA:1-99; B:1-99HIV-1 MUTANT (V82F, I84V) PROTEASE COMPLEXED WITH DMP323
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Strain: bh102. (9)
1BV7A:1-99; B:1-99COUNTERACTING HIV-1 PROTEASE DRUG RESISTANCE: STRUCTURAL ANALYSIS OF MUTANT PROTEASES COMPLEXED WITH XV638 AND SD146, CYCLIC UREA AMIDES WITH BROAD SPECIFICITIES
1BV9A:1-99; B:1-99HIV-1 PROTEASE (I84V) COMPLEXED WITH XV638 OF DUPONT PHARMACEUTICALS
1BWAA:1-99; B:1-99HIV-1 PROTEASE (V82F/I84V) DOUBLE MUTANT COMPLEXED WITH XV638 OF DUPONT PHARMACEUTICALS
1BWBA:1-99; B:1-99HIV-1 PROTEASE (V82F/I84V) DOUBLE MUTANT COMPLEXED WITH SD146 OF DUPONT PHARMACEUTICALS
1HWRA:1-99; B:1-99MOLECULAR RECOGNITION OF CYCLIC UREA HIV PROTEASE INHIBITORS
1QBRA:1-99; B:1-99HIV-1 PROTEASE INHIBITORS WIIH LOW NANOMOLAR POTENCY
1QBSA:1-99; B:1-99HIV-1 PROTEASE INHIBITORS WIIH LOW NANOMOLAR POTENCY
1QBTA:1-99; B:1-99HIV-1 PROTEASE INHIBITORS WIIH LOW NANOMOLAR POTENCY
1QBUA:1-99; B:1-99HIV-1 PROTEASE INHIBITORS WIIH LOW NANOMOLAR POTENCY
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Strain: bh5 isolate. (3)
2F80A:1-99; B:1-99HIV-1 PROTEASE MUTANT D30N COMPLEXED WITH INHIBITOR TMC114
2F81A:1-99; B:101-199HIV-1 PROTEASE MUTANT L90M COMPLEXED WITH INHIBITOR TMC114
2F8GA:1-99; B:101-199HIV-1 PROTEASE MUTANT I50V COMPLEXED WITH INHIBITOR TMC114
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Strain: bh5. (3)
1UPJA:1-99HIV-1 PROTEASE COMPLEX WITH U095438 [3-[1-(4-BROMOPHENYL) ISOBUTYL]-4-HYDROXYCOUMARIN
2UPJA:1-99; B:1-99HIV-1 PROTEASE COMPLEX WITH U100313 ([3-[[3-[CYCLOPROPYL [4-HYDROXY-2OXO-6-[1-(PHENYLMETHYL)PROPYL]-2H-PYRAN-3-YL] METHYL]PHENYL]AMINO]-3-OXO-PROPYL]CARBAMIC ACID TERT-BUTYL ESTER)
7UPJA:1-99; B:1-99HIV-1 PROTEASE/U101935 COMPLEX
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Strain: bh7. (1)
1G35A:1-99; B:1-99CRYSTAL STRUCTURE OF HIV-1 PROTEASE IN COMPLEX WITH INHIBITOR, AHA024
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Strain: gag-pol. (9)
2PWCA:1-99; B:1-99HIV-1 PROTEASE IN COMPLEX WITH A AMINO DECORATED PYRROLIDINE-BASED INHIBITOR
2PWRA:1-99; B:1-99HIV-1 PROTEASE IN COMPLEX WITH A CARBAMOYL DECORATED PYRROLIDINE-BASED INHIBITOR
2QNNA:1-99; B:1-99HIV-1 PROTEASE IN COMPLEX WITH A MULTIPLE DECORATED PYRROLIDINE-BASED INHIBITOR
2QNPA:1-99; B:1-99HIV-1 PROTEASE IN COMPLEX WITH A IODO DECORATED PYRROLIDINE-BASED INHIBITOR
2QNQA:1-99; B:1-99HIV-1 PROTEASE IN COMPLEX WITH A CHLORO DECORATED PYRROLIDINE-BASED INHIBITOR
2R38A:1-99; B:1-99I84V HIV-1 PROTEASE MUTANT IN COMPLEX WITH A CARBAMOYL DECORATED PYRROLIDINE-BASED INHIBITOR
2R3TA:1-99; B:1-99I50V HIV-1 PROTEASE MUTANT IN COMPLEX WITH A CARBAMOYL DECORATED PYRROLIDINE-BASED INHIBITOR
2R3WA:1-99; B:1-99I84V HIV-1 PROTEASE IN COMPLEX WITH A AMINO DECORATED PYRROLIDINE-BASED INHIBITOR
2R43A:1-99; B:1-99I50V HIV-1 PROTEASE IN COMPLEX WITH AN AMINO DECORATED PYRROLIDINE-BASED INHIBITOR
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Strain: hiv-1 d10. Variant: d10. (5)
2CEJA:1-99; B:101-199P1' EXTENDED HIV-1 PROTEASE INHIBITORS ENCOMPASSING A TERTIARY ALCOHOL IN THE TRANSITION-STATE MIMICKING SCAFFOLD
2CEMA:1-99; B:101-199P1' EXTENDED HIV-1 PROTEASE INHIBITORS ENCOMPASSING A TERTIARY ALCOHOL IN THE TRANSITION-STATE MIMICKING SCAFFOLD
2CENA:1-99; B:101-199P1' EXTENDED HIV-1 PROTEASE INHIBITORS ENCOMPASSING A TERTIARY ALCOHOL IN THE TRANSITION-STATE MIMICKING SCAFFOLD
2UXZA:1-99; B:101-199TWO-CARBON-ELONGATED HIV-1 PROTEASE INHIBITORS WITH A TERTIARY-ALCOHOL-CONTAINING TRANSITION-STATE MIMIC
2UY0A:1-99; B:101-199TWO-CARBON-ELONGATED HIV-1 PROTEASE INHIBITORS WITH A TERTIARY-ALCOHOL-CONTAINING TRANSITION-STATE MIMIC
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Strain: hivlai. (1)
1HPXA:1-99; B:1-99HIV-1 PROTEASE COMPLEXED WITH THE INHIBITOR KNI-272
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Strain: hxb2. (3)
1BVEA:1-99; B:1-99HIV-1 PROTEASE-DMP323 COMPLEX IN SOLUTION, NMR, 28 STRUCTURES
1BVGA:1-99; B:1-99HIV-1 PROTEASE-DMP323 COMPLEX IN SOLUTION, NMR MINIMIZED AVERAGE STRUCTURE
2FNTA:1-99; B:1-99CRYSTAL STRUCTURE OF A DRUG-RESISTANT (V82A) INACTIVE (D25N) HIV-1 PROTEASE COMPLEXED WITH AP2V VARIANT OF HIV-1 NC-P1 SUBSTRATE.
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Strain: hxb2. (1)
2FNSA:1-99; B:1-99CRYSTAL STRUCTURE OF WILD-TYPE INACTIVE (D25N) HIV-1 PROTEASE COMPLEXED WITH WILD-TYPE HIV-1 NC-P1 SUBSTRATE.
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Strain: iiib. (3)
1BDLA:1-99; B:1-99HIV-1 (2:31-37) PROTEASE COMPLEXED WITH INHIBITOR SB203386
1BDQA:1-99; B:1-99HIV-1 (2:31-37, 47, 82) PROTEASE COMPLEXED WITH INHIBITOR SB203386
1BDRA:1-99; B:1-99HIV-1 (2: 31, 33-37) PROTEASE COMPLEXED WITH INHIBITOR SB203386
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Strain: isolatebh5. (1)
2AVMA:1-99; B:1-99KINETICS, STABILITY, AND STRUCTURAL CHANGES IN HIGH RESOLUTION CRYSTAL STRUCTURES OF HIV-1 PROTEASE WITH DRUG RESISTANT MUTATIONS L24I, I50V, AND G73S
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Strain: isolatehxb2. (1)
1A30A:1-99; B:1-99HIV-1 PROTEASE COMPLEXED WITH A TRIPEPTIDE INHIBITOR
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Strain: nl4-3. (3)
2HB2A:1-99STRUCTURE OF HIV PROTEASE 6X MUTANT IN APO FORM
2HB4A:1-99STRUCTURE OF HIV PROTEASE NL4-3 IN AN UNLIGANDED STATE
2HC0A:1001-1099; B:2101-2199STRUCTURE OF HIV PROTEASE 6X MUTANT IN COMPLEX WITH AB-2.
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Strain: r8. (10)
2AZ8A:1-99HIV-1 PROTEASE NL4-3 IN COMPLEX WITH INHIBITOR, TL-3
2AZ9A:1-99HIV-1 PROTEASE NL4-3 1X MUTANT
2AZBA:1-99HIV-1 PROTEASE NL4-3 3X MUTANT IN COMPLEX WITH INHIBITOR, TL-3
2AZCA:1-99; B:1-99HIV-1 PROTEASE NL4-3 6X MUTANT
3KF0A:1-99; B:1-99HIV PROTEASE WITH FRAGMENT 4D9 BOUND
3KF1  [entry was replaced by entry 4E43 without any CATH domain information]
3KFNA:1-99; B:1-99HIV PROTEASE (PR) WITH INHIBITOR TL-3 AND FRAGMENT HIT 4D9 BY SOAKING
3KFPA:1-99HIV PROTEASE (PR) WITH INHIBITOR TL-3 BOUND, AND DMSOS IN EXO SITE
3KFRA:1-99; B:1-99HIV PROTEASE (PR) DIMER WITH INHIBITOR TL-3 BOUND AND FRAGMENT 1F1 IN THE OUTSIDE/TOP OF FLAP
3KFSA:1-99; B:1-99HIV PROTEASE (PR) DIMER WITH INHIBITOR TL-3 BOUND AND FRAGMENT 2F4 IN THE OUTSIDE/TOP OF FLAP
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Strain: scs-1. (1)
1PROA:1-99; B:1-99HIV-1 PROTEASE DIMER COMPLEXED WITH A-98881
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Strain: sf2 (1)
2F3KA:1-99; B:1-99SUBSTRATE ENVELOPE AND DRUG RESISTANCE: CRYSTAL STRUCTURE OF R01 IN COMPLEX WITH WILD-TYPE HIV-1 PROTEASE
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Strain: sf2. (22)
2FGUA:1-99; B:1-99X-RAY CRYSTAL STRUCTURE OF HIV-1 PROTEASE T80S VARIANT IN COMPLEX WITH THE INHIBITOR SAQUINAVIR USED TO EXPLORE THE ROLE OF INVARIANT THR80 IN HIV-1 PROTEASE STRUCTURE, FUNCTION, AND VIRAL INFECTIVITY.
2FGVA:1-99; B:1-99X-RAY CRYSTAL STRUCTURE OF HIV-1 PROTEASE T80N VARIANT IN COMPLEX WITH THE INHIBITOR SAQUINAVIR USED TO EXPLORE THE ROLE OF INVARIANT THR80 IN HIV-1 PROTEASE STRUCTURE, FUNCTION, AND VIRAL INFECTIVITY.
2I0AA:1-99; B:1-99CRYSTAL STRUCTURE OF KB-19 COMPLEXED WITH WILD TYPE HIV-1 PROTEASE
2I0DA:1-99; B:1-99CRYSTAL STRUCTURE OF AD-81 COMPLEXED WITH WILD TYPE HIV-1 PROTEASE
2PSUA:1-99; B:1-99CRYSTAL STRUCTURE OF WILD TYPE HIV-1 PROTEASE IN COMPLEX WITH CARB-AD37
2PSVA:1-99; B:1-99CRYSTAL STRUCTURE OF WILD TYPE HIV-1 PROTEASE IN COMPLEX WITH CARB-KB45
2Q3KA:1-99; B:1-99CRYSTAL STRUCTURE OF LYSINE SULFONAMIDE INHIBITOR REVEALS THE DISPLACEMENT OF THE CONSERVED FLAP WATER MOLECULE IN HIV-1 PROTEASE
2Q54A:1-99; B:1-99CRYSTAL STRUCTURE OF KB73 BOUND TO HIV-1 PROTEASE
2Q55A:1-99; B:1-99CRYSTAL STRUCTURE OF KK44 BOUND TO HIV-1 PROTEASE
2Q5KA:1-99; B:1-99CRYSTAL STRUCTURE OF LOPINAVIR BOUND TO WILD TYPE HIV-1 PROTEASE
2QHYA:1-99; B:1-99CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-1-AC86 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
2QHZA:1-99; B:1-99CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-1-AC87 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
2QI0A:1-99; B:1-99CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-1-KK80 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
2QI1A:1-99; B:1-99CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-1-KK81 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
2QI3A:1-99; B:1-99CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-2-AD94 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
2QI4A:1-99; B:1-99CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-2-AD93 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
2QI5A:1-99; B:1-99CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-2-KC08 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
2QI6A:1-99; B:1-99CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-2-KB98 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
2QI7A:1-99; B:1-99CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, MIT-2-AD86 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
3GI4A:1-99; B:1-99CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, KB60 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
3GI5A:1-99; B:1-99CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, KB62 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
3GI6A:1-99; B:1-99CRYSTAL STRUCTURE OF PROTEASE INHIBITOR, AD78 IN COMPLEX WITH WILD TYPE HIV-1 PROTEASE
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Strain: subtypeb. (7)
2O4KA:1-99; B:1-99CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K) IN COMPLEX WITH ATAZANAVIR
2O4LA:1-99; B:1-99CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K, I50V) IN COMPLEX WITH TIPRANAVIR
2O4NA:1-99; B:1-99CRYSTAL STRUCTURE OF HIV-1 PROTEASE (TRM MUTANT) IN COMPLEX WITH TIPRANAVIR
2O4PA:1-99; B:1-99CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K) IN COMPLEX WITH TIPRANAVIR
2O4SA:1-99; B:1-99CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K) IN COMPLEX WITH LOPINAVIR
2PK5A:1-99; B:1-99CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K, L33I, L63I ) IN COMPLEX WITH KNI-10075
2PK6A:1-99; B:1-99CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K, L33I, L63I) IN COMPLEX WITH KNI-10033
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Strain: subtypec. (2)
2R5PA:1-99; B:1-99; C:1-99; D:1-99CRYSTAL STRUCTURE ANALYSIS OF HIV-1 SUBTYPE C PROTEASE COMPLEXED WITH INDINAVIR
2R5QA:1-99; B:1-99; C:1-99; D:1-99CRYSTAL STRUCTURE ANALYSIS OF HIV-1 SUBTYPE C PROTEASE COMPLEXED WITH NELFINAVIR
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Strain: type b. (4)
2PYMA:1-99; B:1-99HIV-1 PR MUTANT IN COMPLEX WITH NELFINAVIR
2PYNA:1-99; B:1-99HIV-1 PR MUTANT IN COMPLEX WITH NELFINAVIR
2Q63A:1-99; B:1-99HIV-1 PR MUTANT IN COMPLEX WITH NELFINAVIR
2Q64A:1-99; B:1-99HIV-1 PR MUTANT IN COMPLEX WITH NELFINAVIR
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Strain: x90. (2)
1YTGA:1-99; B:1-99SIV PROTEASE CRYSTALLIZED WITH PEPTIDE PRODUCT
1YTHA:1-99; B:1-99SIV PROTEASE CRYSTALLIZED WITH PEPTIDE PRODUCT
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Variant: bh102isolate. (1)
1HVHA:1-99; B:1-99NONPEPTIDE CYCLIC CYANOGUANIDINES AS HIV PROTEASE INHIBITORS
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Variant: d10. (1)
2BQVA:1-99; B:101-199HIV-1 PROTEASE IN COMPLEX WITH INHIBITOR AHA455
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Variant: isolate lv. (1)
1G2KA:1-99; B:1-99HIV-1 PROTEASE WITH CYCLIC SULFAMIDE INHIBITOR, AHA047
(-)
Human immunodeficiency virus 1. Organism_taxid: 11676. Variant: sf1 isolate. (3)
1AIDA:1-99; B:1-99STRUCTURE OF A NON-PEPTIDE INHIBITOR COMPLEXED WITH HIV-1 PROTEASE: DEVELOPING A CYCLE OF STRUCTURE-BASED DRUG DESIGN
2AIDA:1-99; B:1-99STRUCTURE OF A NON-PEPTIDE INHIBITOR COMPLEXED WITH HIV-1 PROTEASE: DEVELOPING A CYCLE OF STRUCTURE-BASED DRUG DESIGN
3AIDA:1-99; B:1-99A NEW CLASS OF HIV-1 PROTEASE INHIBITOR: THE CRYSTALLOGRAPHIC STRUCTURE, INHIBITION AND CHEMICAL SYNTHESIS OF AN AMINIMIDE PEPTIDE ISOSTERE
(-)
Human immunodeficiency virus 1. Organism_taxid: 505184. Strain: subtype a. (1)
3IXOA:1-99; B:1-99CRYSTAL STRUCTURE OF UNCOMPLEXED HIV_1 PROTEASE SUBTYPE A
(-)
Human immunodeficiency virus 1. Strain: nh1. (1)
3D3TA:1-99; B:1-99CRYSTAL STRUCTURE OF HIV-1 CRF01_AE IN COMPLEX WITH THE SUBSTRATE P1-P6
(-)
Human immunodeficiency virus 1. Strain: subtype c. (1)
2R8NA:1-99STRUCTURAL ANALYSIS OF THE UNBOUND FORM OF HIV-1 SUBTYPE C PROTEASE
(-)
Human immunodeficiency virus 2. Organism_taxid: 11709. (1)
1HSIA:1-99; B:1-99CRYSTAL STRUCTURE AT 1.9 ANGSTROMS RESOLUTION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) II PROTEASE COMPLEXED WITH L-735,524, AN ORALLY BIOAVAILABLE INHIBITOR OF THE HIV PROTEASES
(-)
Human immunodeficiency virus 2. Organism_taxid: 11709. (11)
1IDAA:1-99; B:1-99CRYSTAL STRUCTURES OF HIV-2 PROTEASE IN COMPLEX WITH INHIBITORS CONTAINING THE HYDROXYETHYLAMINE DIPEPTIDE ISOSTERE
1IDBA:1-99; B:1-99CRYSTAL STRUCTURES OF HIV-2 PROTEASE IN COMPLEX WITH INHIBITORS CONTAINING THE HYDROXYETHYLAMINE DIPEPTIDE ISOSTERE
1IVPA:1-99; B:1-99THE CRYSTALLOGRAPHIC STRUCTURE OF THE PROTEASE FROM HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 WITH TWO SYNTHETIC PEPTIDIC TRANSITION STATE ANALOG INHIBITORS
1IVQA:1-99; B:1-99THE CRYSTALLOGRAPHIC STRUCTURE OF THE PROTEASE FROM HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 WITH TWO SYNTHETIC PEPTIDIC TRANSITION STATE ANALOG INHIBITORS
2HPEA:1-99; B:1-99COMPARISON OF THE STRUCTURES OF HIV-2 PROTEASE COMPLEXES IN THREE CRYSTAL SPACE GROUPS WITH AN HIV-1 PROTEASE COMPLEX STRUCTURE
2HPFA:1-99; B:1-99COMPARISON OF THE STRUCTURES OF HIV-2 PROTEASE COMPLEXES IN THREE CRYSTAL SPACE GROUPS WITH AN HIV-1 PROTEASE COMPLEX STRUCTURE
2MIPA:1-99; B:1-99; C:1-99; D:1-99CRYSTAL STRUCTURE OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) TYPE 2 PROTEASE IN COMPLEX WITH A REDUCED AMIDE INHIBITOR AND COMPARISON WITH HIV-1 PROTEASE STRUCTURES
3UPJA:1-99; B:3-99HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 PROTEASE MUTANT WITH LYS 57 REPLACED BY LEU (K57L) COMPLEX WITH U096333 [4-HYDROXY-3-[1-(PHENYL) PROPYL]-7-METHOXYCOUMARIN]
4UPJA:1-99; B:1-99HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 PROTEASE MUTANT WITH LYS 57 REPLACED BY LEU (K57L) COMPLEX WITH U097410 [4-HYDROXY-3-[1-[3-[[[[(TERT-BUTYLOXYCARBONYL) AMINOMETHYL]CARBONYL]AMINO]PHENYL]PROPYL]COUMARIN
5UPJA:1-99; B:1-99HIV-2 PROTEASE/U99283 COMPLEX
6UPJA:1-99; B:1-99HIV-2 PROTEASE/U99294 COMPLEX
(-)
Human immunodeficiency virus 2. Organism_taxid: 11709. Cell_line: s2. (1)
1HIIA:1-99; B:1-99COMPARATIVE ANALYSIS OF THE X-RAY STRUCTURES OF HIV-1 AND HIV-2 PROTEASES IN COMPLEX WITH CGP 53820, A NOVEL PSEUDOSYMMETRIC INHIBITOR
(-)
Human immunodeficiency virus 2. Organism_taxid: 11709. Strain: rod isolate. (1)
1JLDA:1-99; B:1-99POTENT HIV PROTEASE INHIBITORS CONTAINING A NOVEL (HYDROXYETHYL)AMIDE ISOSTERE
(-)
Human immunodeficiency virus type 1 (3)
3BC4A:1-99I84V HIV-1 PROTEASE IN COMPLEX WITH A PYRROLIDINE DIESTER
3BGBA:1-99; B:1-99HIV-1 PROTEASE IN COMPLEX WITH A ISOBUTYL DECORATED OLIGOAMINE
3BGCA:1-99; B:1-99HIV-1 PROTEASE IN COMPLEX WITH A BENZYL DECORATED OLIGOAMINE
(-)
Human immunodeficiency virus type 1 (bh5 isolate). Organism_taxid: 11682. Strain: bh5 isolate. (8)
2AOCA:1-99; B:101-199CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE MUTANT I84V WITH A SUBSTRATE ANALOG P2-NC
2AODA:1-99; B:101-199CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE WITH A SUBSTRATE ANALOG P2-NC
2AOEA:1-99; B:101-199CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE MUTANT V82A WITH A SUBSTRATE ANALOG CA-P2
2AOGA:1-99; B:101-199CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE MUTANT V82A WITH A SUBSTRATE ANALOG P2-NC
2AOHA:1-99; B:101-199CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE MUTANT V82A WITH A SUBSTRATE ANALOG P6-PR
2AOIA:1-99; B:101-199CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE WITH A SUBSTRATE ANALOG P1-P6
2AOJA:1-99; B:101-199CRYSTAL STRUCTURE ANALYSIS OF HIV-1 PROTEASE WITH A SUBSTRATE ANALOG P6-PR
2AVQA:1-99; B:1-99KINETICS, STABILITY, AND STRUCTURAL CHANGES IN HIGH RESOLUTION CRYSTAL STRUCTURES OF HIV-1 PROTEASE WITH DRUG RESISTANT MUTATIONS L24I, I50V, AND G73S
(-)
Human immunodeficiency virus type 1 (bru isolate). Organism_taxid: 11686. (1)
3BHEA:1-99; B:1-99HIV-1 PROTEASE IN COMPLEX WITH A THREE ARMED PYRROLIDINE DERIVATIVE
(-)
Human immunodeficiency virus type 1 (bru isolate). Organism_taxid: 11686. (1)
1HHPA:1-99THE THREE-DIMENSIONAL STRUCTURE OF THE ASPARTYL PROTEASE FROM THE HIV-1 ISOLATE BRU
(-)
Human immunodeficiency virus type 1 (bru isolate). Organism_taxid: 11686. Strain: type b. (1)
3GGUA:1-99; B:1-99HIV PR DRUG RESISTANT PATIENT'S VARIANT IN COMPLEX WITH DARUNAVIR
(-)
Human immunodeficiency virus type 1 (clone 12). Organism_taxid: 11679. (1)
3TLHA:1-99STRUCTURAL STUDIES OF HIV AND FIV PROTEASES COMPLEXED WITHAN EFFICIENT INHIBITOR OF FIV PR
(-)
Human immunodeficiency virus type 1 (clone 12). Organism_taxid: 11679.Variant: hxb-3. (1)
1HXBA:1-99; B:1-99HIV-1 PROTEINASE COMPLEXED WITH RO 31-8959
(-)
Human immunodeficiency virus type 1 (isolate hxb2 group m subtype b).Hiv-1, hiv-1 m:b_hxb2r. Organism_taxid: 11706. (1)
3DOXA:1-99; A:1001-1099X-RAY STRUCTURE OF HIV-1 PROTEASE IN SITU PRODUCT COMPLEX
(-)
Human immunodeficiency virus type 1 bh10. Organism_taxid: 11678. (1)
1SBGA:1-99; B:1-99AN ORALLY-BIOAVAILABLE HIV-1 PROTEASE INHIBITOR CONTAINING AN IMIDAZOLE-DERIVED PEPTIDE BOND REPLACEMENT. CRYSTALLOGRAPHIC AND PHARMACOKINETIC ANALYSIS
(-)
Human immunodeficiency virus type 1 bh10. Organism_taxid: 11678. Strain: bh5 isolate. (2)
3B7VA:1-99; B:101-199HIV-1 PROTEASE COMPLEXED WITH GEM-DIOL-AMINE TETRAHEDRAL INTERMEDIATE NLLTQI
3B80A:1-99; B:101-199HIV-1 PROTEASE MUTANT I54V COMPLEXED WITH GEM-DIOL-AMINE INTERMEDIATE NLLTQI
(-)
Human immunodeficiency virus type 1. (2)
3CYWA:1-99; B:1-99EFFECT OF FLAP MUTATIONS ON STRUCTURE OF HIV-1 PROTEASE AND INHIBITION BY SAQUINAVIR AND DARUNAVIR
3D1XA:1-99; B:1-99CRYSTAL STRUCTURE OF HIV-1 MUTANT I54M AND INHIBITOR SAQUINAVIR
(-)
Human immunodeficiency virus type 1. Organism_taxid: 11686. (1)
3I8WA:1-99CRYSTAL STRUCTURE OF A METALLACARBORANE INHIBITOR BOUND TO HIV PROTEASE
(-)
Human immunodeficiency virus type 2 (isolate rod). Organism_taxid: 11720. (3)
3EBZA:1-99; B:101-199HIGH RESOLUTION HIV-2 PROTEASE STRUCTURE IN COMPLEX WITH CLINICAL DRUG DARUNAVIR
3EC0A:1-99; B:101-199HIGH RESOLUTION HIV-2 PROTEASE STRUCTURE IN COMPLEX WITH ANTIVIRAL INHIBITOR GRL-06579A
3ECGA:1-99; B:101-199HIGH RESOLUTION HIV-2 PROTEASE STRUCTURE IN COMPLEX WITH ANTIVIRAL INHIBITOR GRL-98065
(-)
Human immunodeficiency virus. Organism_taxid: 12721. (1)
1KZKA:1-99; B:1-99JE-2147-HIV PROTEASE COMPLEX
(-)
Human immunodeficiency virus. Organism_taxid: 12721. Strain: bh10. (3)
1D4HA:1-99; B:101-199HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA435
1D4IA:1-99; B:101-199HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR BEA425
1D4JA:1-99; B:101-199HIV-1 PROTEASE IN COMPLEX WITH THE INHIBITOR MSL370
(-)
Hypocrea jecorina (Hypocrea jecorina) (1)
3EMYA:171-326; A:2-170CRYSTAL STRUCTURE OF TRICHODERMA REESEI ASPARTIC PROTEINASE COMPLEXED WITH PEPSTATIN A
(-)
Hypocrea jecorina (Trichoderma reesei) (1)
3C9XA:171-326; A:2-170CRYSTAL STRUCTURE OF TRICHODERMA REESEI ASPARTIC PROTEINASE
(-)
Irpex lacteus. Organism_taxid: 5319. (1)
1WKRA:1-170; A:171-340CRYSTAL STRUCTURE OF ASPARTIC PROTEINASE FROM IRPEX LACTEUS
(-)
Malaria parasite p (Plasmodium falciparum) (14)
1LEEA:176-329; A:1-175CRYSTAL STRUCTURE OF PLASMEPSIN FROM P. FALCIPARUM IN COMPLEX WITH INHIBITOR RS367
1LF2A:176-329; A:1-175CRYSTAL STRUCTURE OF PLASMEPSIN II FROM P FALCIPARUM IN COMPLEX WITH INHIBITOR RS370
1LF3A:176-329; A:1-175CRYSTAL STRUCTURE OF PLASMEPSIN II FROM P FALCIPARUM IN COMPLEX WITH INHIBITOR EH58
1LF4A:176-328; A:1-175STRUCTURE OF PLASMEPSIN II
1LS5A:176-328; B:176-328; A:1-175; B:1-175CRYSTAL STRUCTURE OF PLASMEPSIN IV FROM P. FALCIPARUM IN COMPLEX WITH PEPSTATIN A
1M43A:176-329; B:176-329; A:1-175; B:1-175CRYSTAL STRUCTURE OF PMII IN COMPLEX WITH PEPSTATIN A TO 2.4 A
1ME6A:176-329; B:176-329; A:1-175; B:1-175CRYSTAL STRUCTURE OF PLASMEPSIN II, AN ASPARTYL PROTEASE FROM PLASMODIUM FALCIPARUM, IN COMPLEX WITH A STATINE-BASED INHIBITOR
1PFZB:176-327; B:15-175; C:15-175; D:15-175; A:15-175; A:79P-14,A:176-328; C:176-327; D:176-328PROPLASMEPSIN II FROM PLASMODIUM FALCIPARUM
1SMEA:176-329; B:176-329; A:1-175; B:1-175PLASMEPSIN II, A HEMOGLOBIN-DEGRADING ENZYME FROM PLASMODIUM FALCIPARUM, IN COMPLEX WITH PEPSTATIN A
1XDHA:176-329; B:176-329; A:1-175; B:1-175STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH PEPSTATIN A
1XE5A:176-329; A:1-175; B:1-175; B:176-329STRUCTURE OF PLASMEPSIN II IN COMPLEX OF AN PEPSTATIN ANALOGUE
1XE6A:176-329; B:176-329; A:1-175; B:1-175STRUCTURE OF PLASMEPSIN II IN COMPLEX OF AN PEPSTATIN ANALOGUE
2IGXA:176-329; A:1-175ACHIRAL, CHEAP AND POTENT INHIBITORS OF PLASMEPSINS II
2IGYA:176-329; B:176-329; A:1-175; B:1-175ACHIRAL, CHEAP AND POTENT INHIBITORS OF PLASMEPSINS II
(-)
Malaria parasite p (Plasmodium vivax) (2)
1MIQA:176-327; B:176-327; A:1-175; B:1-175CRYSTAL STRUCTURE OF PROPLASMEPSIN FROM THE HUMAN MALARIAL PATHOGEN PLASMODIUM VIVAX
1QS8A:176-327; B:176-327; A:1-175; B:1-175CRYSTAL STRUCTURE OF THE P. VIVAX ASPARTIC PROTEINASE PLASMEPSIN COMPLEXED WITH THE INHIBITOR PEPSTATIN A
(-)
Mucor miehei (Rhizomucor miehei) (2)
2ASIA:187-360; A:6-186ASPARTIC PROTEINASE
2RMPA:187-359; A:6-186RMP-PEPSTATIN A COMPLEX
(-)
Penicillium janthinellum. Organism_taxid: 5079 (7)
1BXOA:171-322; A:6-170ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL CYCLO[(2S)-2-[[(1R)-1-(N-(L-N-(3-METHYLBUTANOYL)VALYL-L-ASPARTYL)AMINO)-3-METHYLBUT YL] HYDROXYPHOSPHINYLOXY]-3-(3-AMINOMETHYL) PHENYLPROPANOATE
1BXQA:171-322; A:6-170ACID PROTEINASE (PENICILLOPEPSIN) COMPLEX WITH PHOSPHONATE INHIBITOR.
2WEAA:171-322; A:6-170ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL[CYCLO-7[(2R)-((N-VALYL) AMINO)-2-(HYDROXYL-(1S)-1-METHYOXYCARBONYL-2-PHENYLETHOXY) PHOSPHINYLOXY-ETHYL]-1-NAPHTHALENEACETAMIDE], SODIUM SALT
2WEBA:171-322; A:6-170ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL(2S)-[1-(((N-FORMYL)-L-VALYL)AMINO-2-(2-NAPHTHYL)ETHYL)HYDROXYPHOSPHINYLOXY]-3-PHENYLPROPANOATE, SODIUM SALT
2WECA:171-322; A:6-170ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL(2S)-[1-(((N-(1-NAPHTHALENEACETYL))-L-VALYL)AMINOMETHYL)HYDROXY PHOSPHINYLOXY]-3-PHENYLPROPANOATE, SODIUM SALT
2WEDA:171-322; A:6-170ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE MACROCYCLIC INHIBITOR:METHYL[CYCLO-7[(2R)-((N-VALYL)AMINO)-2-(HYDROXYL-(1S)-1-METHYOXYCARBONYL-2-PHENYLETHOXY)PHOSPHINYLOXY-ETHYL]-1-NAPHTHALENEACETAMIDE], SODIUM SALT
3APPA:171-322; A:6-170STRUCTURE AND REFINEMENT OF PENICILLOPEPSIN AT 1.8 ANGSTROMS RESOLUTION
(-)
Penicillium janthinellum. Organism_taxid: 5079. (1)
1APUE:171-322; E:6-170CRYSTALLOGRAPHIC ANALYSIS OF A PEPSTATIN ANALOGUE BINDING TO THE ASPARTYL PROTEINASE PENICILLOPEPSIN AT 1.8 ANGSTROMS RESOLUTION
(-)
Penicillium janthinellum. Organism_taxid: 5079. (3)
1PPKE:171-322; E:6-170CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION STATE MIMICS BOUND TO PENICILLOPEPSIN: PHOSPHOROUS-CONTAINING PEPTIDE ANALOGUES
1PPLE:171-322; E:6-170CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION-STATE MIMICS BOUND TO PENICILLOPEPSIN: PHOSPHORUS-CONTAINING PEPTIDE ANALOGUES
1PPME:171-322; E:6-170CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION-STATE MIMICS BOUND TO PENICILLOPEPSIN: PHOSPHORUS-CONTAINING PEPTIDE ANALOGUES
(-)
Penicillium vitale (Penicillium janthinellum) (3)
1APTE:171-322; E:6-170CRYSTALLOGRAPHIC ANALYSIS OF A PEPSTATIN ANALOGUE BINDING TO THE ASPARTYL PROTEINASE PENICILLOPEPSIN AT 1.8 ANGSTROMS RESOLUTION
1APVE:171-322; E:6-170CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION STATE MIMICS BOUND TO PENICILLOPEPSIN: DIFLUOROSTATINE-AND DIFLUOROSTATONE-CONTAINING PEPTIDES
1APWE:171-322; E:6-170CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION STATE MIMICS BOUND TO PENICILLOPEPSIN: DIFLUOROSTATINE-AND DIFLUOROSTATONE-CONTAINING PEPTIDES
(-)
Pig (Sus scrofa) (8)
1F34A:171-325; A:1-170CRYSTAL STRUCTURE OF ASCARIS PEPSIN INHIBITOR-3 BOUND TO PORCINE PEPSIN
1PSAA:171-326; A:1-170; B:1-170; B:171-326STRUCTURE OF A PEPSIN(SLASH)RENIN INHIBITOR COMPLEX REVEALS A NOVEL CRYSTAL PACKING INDUCED BY MINOR CHEMICAL ALTERATIONS IN THE INHIBITOR
1YX9A:171-327; A:1-170EFFECT OF DIMETHYL SULPHOXIDE ON THE CRYSTAL STRUCTURE OF PORCINE PEPSIN
2PSGA:171-326; A:1-170REFINED STRUCTURE OF PORCINE PEPSINOGEN AT 1.8 ANGSTROMS RESOLUTION
3PEPA:171-326; A:1-170REVISED 2.3 ANGSTROMS STRUCTURE OF PORCINE PEPSIN. EVIDENCE FOR A FLEXIBLE SUBDOMAIN
3PSGA:171-325; A:1-170THE HIGH RESOLUTION CRYSTAL STRUCTURE OF PORCINE PEPSINOGEN
4PEPA:171-326; A:1-170THE MOLECULAR AND CRYSTAL STRUCTURES OF MONOCLINIC PORCINE PEPSIN REFINED AT 1.8 ANGSTROMS RESOLUTION
5PEPA:171-327; A:1-170X-RAY ANALYSES OF ASPARTIC PROTEASES. II. THREE-DIMENSIONAL STRUCTURE OF THE HEXAGONAL CRYSTAL FORM OF PORCINE PEPSIN AT 2.3 ANGSTROMS RESOLUTION
(-)
Plasmodium falciparum 3d7. Organism_taxid: 36329. (1)
3FNSA:173-326; B:173-326; A:0-172; B:0-172CRYSTAL STRUCTURE OF HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM
(-)
Plasmodium falciparum 3d7. Organism_taxid: 36329. Strain: 3d7. (3)
2R9BA:176-329; B:176-329; A:1-175; B:1-175STRUCTURAL ANALYSIS OF PLASMEPSIN 2 FROM PLASMODIUM FALCIPARUM COMPLEXED WITH A PEPTIDE-BASED INHIBITOR
3FNTA:173-326; A:2-172CRYSTAL STRUCTURE OF PEPSTATIN A BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM
3FNUA:173-327; B:0-172; C:0-172; D:0-172; B:173-327; C:173-327; D:173-327; A:0-172CRYSTAL STRUCTURE OF KNI-10006 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM
(-)
Plasmodium falciparum. Organism_taxid: 5833. (4)
1W6HA:176-329; B:176-329; A:1-175; B:1-175NOVEL PLASMEPSIN II-INHIBITOR COMPLEX
1W6IA:176-329; A:1-175; C:1-175; C:176-329PLASMEPSIN II-PEPSTATIN A COMPLEX
2BJUA:176-329; A:1-175PLASMEPSIN II COMPLEXED WITH A HIGHLY ACTIVE ACHIRAL INHIBITOR
3F9QA:176-329; A:1-175RE-REFINEMENT OF UNCOMPLEXED PLASMEPSIN II FROM PLASMODIUM FALCIPARUM.
(-)
Plasmodium malariae. Organism_taxid: 5858. (1)
2ANLA:176-327; B:176-327; A:1-175; B:1-175X-RAY CRYSTAL STRUCTURE OF THE ASPARTIC PROTEASE PLASMEPSIN 4 FROM THE MALARIAL PARASITE PLASMODIUM MALARIAE BOUND TO AN ALLOPHENYLNORSTATINE BASED INHIBITOR
(-)
Pneumophila str (Legionella pneumophila subsp) (1)
2PMAA:23-158; B:23-158STRUCTURAL GENOMICS, THE CRYSTAL STRUCTURE OF A PROTEIN LPG0085 WITH UNKNOWN FUNCTION (DUF785) FROM LEGIONELLA PNEUMOPHILA SUBSP. PNEUMOPHILA STR. PHILADELPHIA 1.
(-)
Rhizomucor pusillus. Organism_taxid: 4840 (1)
1MPPA:170-332; A:1-169X-RAY ANALYSES OF ASPARTIC PROTEINASES. V. STRUCTURE AND REFINEMENT AT 2.0 ANGSTROMS RESOLUTION OF THE ASPARTIC PROTEINASE FROM MUCOR PUSILLUS
(-)
Rous sarcoma virus. (1)
1BAIA:1-124; B:1-124CRYSTAL STRUCTURE OF ROUS SARCOMA VIRUS PROTEASE IN COMPLEX WITH INHIBITOR
(-)
Rous sarcoma virus. Organism_taxid: 11886 (1)
2RSPA:1-124; B:1-124STRUCTURE OF THE ASPARTIC PROTEASE FROM ROUS SARCOMA RETROVIRUS REFINED AT 2 ANGSTROMS RESOLUTION
(-)
Simian immunodeficiency virus. Organism_taxid: 11723 (1)
1SIVA:1-99; B:1-99THREE-DIMENSIONAL STRUCTURE OF A SIV PROTEASE(SLASH)INHIBITOR COMPLEX. IMPLICATIONS FOR THE DESIGN OF HIV-1 AND HIV-2 PROTEASE INHIBITORS
(-)
Simian immunodeficiency virus. Organism_taxid: 11723. (1)
1TCWA:1-99; B:1-99SIV PROTEASE COMPLEXED WITH INHIBITOR SB203386
(-)
Simian immunodeficiency virus. Organism_taxid: 11723. Cell_line: s2. (1)
1SIPA:1-99ALTERNATIVE NATIVE FLAP CONFORMATION REVEALED BY 2.3 ANGSTROMS RESOLUTION STRUCTURE OF SIV PROTEINASE
(-)
Simian immunodeficiency virus. Organism_taxid: 11723. Expression_system_vector_type: plasmid (1)
2SAMA:1-99STRUCTURE OF THE PROTEASE FROM SIMIAN IMMUNODEFICIENCY VIRUS: COMPLEX WITH AN IRREVERSIBLE NON-PEPTIDE INHIBITOR
(-)
Simian immunodeficiency virus. Organism_taxid: 11723. Strain: x90. (2)
1YTIA:1-99SIV PROTEASE CRYSTALLIZED WITH PEPTIDE PRODUCT
1YTJA:1-99SIV PROTEASE CRYSTALLIZED WITH PEPTIDE PRODUCT
(-)
Simian immunodeficiency virus. Organism_taxid: 11723. Strain: x90. Variant: siv(mac)239. (1)
1AZ5A:1-99UNLIGANDED SIV PROTEASE STRUCTURE IN AN "OPEN" CONFORMATION
(-)
Simian retrovirus 1. Organism_taxid: 11942. (1)
1NSOA:1-107FOLDED MONOMER OF PROTEASE FROM MASON-PFIZER MONKEY VIRUS
(-)
Wheat (Triticum aestivum) (1)
3HD8C:1-182; A:1-182; C:183-385; A:183-386CRYSTAL STRUCTURE OF THE TRITICUM AESTIVUM XYLANASE INHIBITOR-IIA IN COMPLEX WITH BACILLUS SUBTILIS XYLANASE
(-)
Yeast (Candida albicans) (2)
2QZWA:173-342; B:173-342; A:1-172; B:1-172SECRETED ASPARTIC PROTEINASE (SAP) 1 FROM CANDIDA ALBICANS
2QZXA:173-342; B:173-342; A:1-172; B:1-172SECRETED ASPARTIC PROTEINASE (SAP) 5 FROM CANDIDA ALBICANS